Loma Linda University

TheScholarsRepository@LLU: Digital Archive of Research,
Scholarship & Creative Works
Loma Linda University Electronic Theses, Dissertations & Projects
6-2009

A Psychoeducational Group Intervention for Fibromyalgia Patients
Derek O. Bacchus

Follow this and additional works at: https://scholarsrepository.llu.edu/etd
Part of the Clinical Psychology Commons, Cognitive Behavioral Therapy Commons, and the Pain
Management Commons

Recommended Citation
Bacchus, Derek O., "A Psychoeducational Group Intervention for Fibromyalgia Patients" (2009). Loma
Linda University Electronic Theses, Dissertations & Projects. 898.
https://scholarsrepository.llu.edu/etd/898

This Dissertation is brought to you for free and open access by TheScholarsRepository@LLU: Digital Archive of
Research, Scholarship & Creative Works. It has been accepted for inclusion in Loma Linda University Electronic
Theses, Dissertations & Projects by an authorized administrator of TheScholarsRepository@LLU: Digital Archive of
Research, Scholarship & Creative Works. For more information, please contact scholarsrepository@llu.edu.

UNIVERSITY LIBRARIES
LOMA LINDA, CALIFORNIA
LOMA LINDA UNIVERSITY
School of Science and Technology
in conjunction with the
Faculty of Psychology

A Psychoeducational Group Intervention for Fibromyalgia Patients
by

Derek O. Bacchus

A Dissertation submitted in partial satisfaction of
the requirements for the degree of
Doctor of Philosophy in Clinical Psychology

June 2009

©2009
Derek Orlando Bacchus
All Right Reserved

Each person whose signature appears below certifies that this thesis in his/her opinion is
adequate, in scope and quality, as a dissertation for the degree Doctor of Philosophy.

2
Kendal C. Boyd, Assistant Professor of Psychology
Louis Jenking/Professor of Psychology

Emmanuel Katsaros, Assistant Professor of Medicine

Ja^on^fwen, AWsfant Professor of Psychology

David Vermeersch, Associate Professor of Psychology

in

. Chairperson

ACKNOWLEDGEMENTS

I would like to thank my research guidance committee, Kendal C. Boyd, Ph.D.,
Louis Jenkins, Ph.D., Emmanuel Katsaros, D.O., Jason Owen, Ph.D., and David
Vermeersch, Ph.D., for their input and instruction that has been invaluable to my
academic development. I am further indebted to Ms. Shari Lane and Ms. Leticia Ortiz,
for their assistance in navigating administrative requirements in the Department of
Psychology. Lastly, I wish to recognize my research lab colleagues Eugene Moynier, Eric
Kloeppel, and George Vasquez for their assistance in data collection for this study.

iv

CONTENTS

Approval Page

in

Acknowledgements

iv

List of Tables

vn

List of Figures

vm

List of Abbreviations

ix

Abstract

x

Chapter
1. Introduction

1

Biomedical Causes....................
Biomedical Treatments.............
Psychosocial Causes.................
Psychosocial Treatments...........
Biopsychosocial Considerations
Hypotheses................................

,4

8
16
,21
35
38
,41

2. Method

,41
,41

Participants
Instruments

,41

Demographics..
Fibromyalgia....
Depression.......
Catastrophizing
Quality of Life..

,42
,43
,44

,45
.45

Procedure

,48

3. Results

,48
51

Data Screening
Data Analysis..
Hypothesis #1
Hypothesis #2

51
54

v

55
57
58
59
60
62

Hypothesis #3...........
Hypothesis #4...........
Hypothesis #5...........
Hypothesis #6...........
Further Analyses .....
Post-Hoc Exploration

69

4. Discussion

75

Limitations.
Conclusions

78
80

References
Appendix
A. A Modified Hollingshead 3-Factor Index of Social Status

93

B. The Short-Form McGill Pain Questionnaire.

95

C. Center for Epidemiologic Studies Depression Scale

96

D. Coping Strategies Questionnaire.

98

E. World Health Organization Quality of Life Assessment—Abbreviated

100

F. Informed Consent.

106

vi

TABLES
Page

Table
1.

Sample Demographics

,49

2.

Means, Standard Deviations, and Skewness Statistics

50

3.

Correlations Between Demographic and Study Variables

51

4.

Comparison of Between-Group Differences

52

5.

Comparison of Between-Group Change Rate Scores

53

6.

Within-Group Depression Changes

54

7.

Within-Group Catastrophizing Changes

55

8.

Within-Group Quality of Life Changes

57

9.

Within-Group Pain Changes

58

10.

Group 1 Outcome Score Changes at Follow-Up

59

11.

Group 2 Outcome Score Changes Following Baseline

60

12.

Between-Group Outcome Score Differences for Attention Diversion and
Cognitive Coping.......................................................................................

61

13.

Between-Group Differences in Exercise Levels

62

14.

Quality of Life Case Analysis

63

15.

Catastrophizing Case Analysis

64

16.

Pain Case Analysis

65

17.

Cognitive Coping Case Analysis

66

vn

FIGURES

Page

Figure
1. Biomedical Theories of FMS Etiology

35

2. Psychosocial Theories of FMS Etiology.

36

3. Biopsychosocial Model of FMS Etiology,

37

4. Biopsychosocial Model for FMS Treatment

38

5. Between-Group Differences in Outcome Scores and Rate of Change Scores
for Depression................................................................................................ .

53

6. Between-Group Differences in Outcome Scores and Rate of Change Scores
for Catastrophizing.........................................................................................

55

7. Between-Group Differences in Outcome Scores and Rate of Change Scores
for Quality of Life..........................................................................................

56

8. Between-Group Differences in Outcome Scores and Rate of Change Scores
for FMS Pain..................................................................................................

58

9. Sequence Plot of Group 2 Members’ Quality of Life Improvement

64

10. Sequence Plot of Group 2 Members’ Catastrophizing Improvement

65

11. Sequence Plot of Group 2 Member Pain Improvement

66

12. Sequence Plot of Group 2 Member Cognitive Coping Improvement,

67

vm

ABBREVIATIONS

BPD

Borderline Personality Disorder

BDI

Beck Depression Inventory

BID

Twice Daily

CBT

Cognitive-Behavioral Therapy

CES-D

Center for Epidemiologic Studies Depression Scale

CWP

Chronic Widespread Pain

CSQ

Coping Strategies Questionnaire

FMS

Fibromyalgia Syndrome

MDD

Major Depressive Disorder

MMPI-2

Minnesota Multiphasic Personality Inventory—2nd Edition

NMDA

N-methyl-D-aspartate

PRI

Pain Rating Index

QD

Every Day

SES

Socio-Economic Status

SF-MPQ

Short-Form Melzack Pain Questionnaire

SSRI

Selective Serotonin Reuptake Inhibitor

SNRI

Selective Norepinephrine Reuptake Inhibitor

TM

Transtheoretical Model

TOMM

Test of Memory Malingering

VAS

Visual Analogue Scale

WHOQOL-BREF

World Health Organization Quality of Life AssessmentAbbreviated Version

ix

ABSTRACT OF THE DISSERTATION
A Psychoeducational Group
Intervention for Fibromyalgia Patients
by
Derek Orlando Bacchus
Doctor of Philosophy, Graduate Program in Psychology
Loma Linda University, June 2009
Dr. Kendal Boyd, Chairperson

This study examined the effect of a multidisciplinary psychoeducational treatment
group on Fibromyalgia Syndrome (FMS) pain, depression, catastrophizing, and quality of
life. The Short-Form McGill Pain Questionnaire (SF-MPQ), Center for Epidemiologic
Studies Depression Scale (CES-D), Coping Strategies Questionnaire (CSQ), and the
World Health Organization Quality of Life Assessment—Abbreviated Version were used
to assess these constructs in 15 participants. The sample was composed entirely of female
participants and was predominantly middle aged, which is typical of the FMS population.
Two separate groups of FMS patients—seven in Group 1, eight in Group 2—completed a
10-week psychoeducational intervention where they were presented with information
regarding symptom management as well as psychoeducational materials to individually
complete.
This study used paired sample Mests to measure pre/post within-group differences
and independent-sample /-tests to assess between-group and change rate differences.
Group 1 demonstrated improvements with regard to pain and catastrophizing, but only
pain reductions were maintained at a 10-week follow-up. Group 2 exhibited gains for the
outcomes variables of depression and quality of life. Single-Vcase analyses generated

x

support for an intervention effect on at least one outcome variable for six of the eight
individuals in Group 2.
Despite the limits of small sample size, depressed statistical power, and high
outcome score variability, modest support was found for the positive effect of a
psychoeducational intervention on FMS symptom management.
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Introduction

Fibromyalgia Syndrome (FMS) is a musculoskeletal syndrome that is
characterized by various physical symptoms, including generalized pain, stiffness, tender
points, sleep disturbances, swelling, numbness, headaches, and bowel irritability
(Goldenberg, 1987). Recently, the FMS diagnosis has come to include cognitive
symptoms as well, such as attention and concentration impairments generally termed
“fibro-fog” (Williams & Gracely, 2007). There is no clearly outlined etiology of FMS,
and various disciplines have put forth hypotheses regarding the possible causal
mechanisms that function to produce FMS (Arnold, Keck & Welge, 2000; Nicassio,
Schoenfeld-Smith, Radojevic, & Schuman, 1995).
Recent prevalence estimates suggest that FMS affects about 2-6% of the general
United States population (Harden et ah, 2007, About Fibromyalgia, n.d.). This translates
to roughly 6-8 million patients who experience FMS symptoms. The FMS population is
predominantly female, with some estimates being as high as 90% overall (Kersh et al.,
2001; Buskila, 2001). Females over the age of 30 also seem to be more likely to
experience FMS symptoms (Kersh et al., 2001). Even though males do represent a small
slice of the total FMS population, the bulk of research regarding FMS causes and
treatments has been carried out on largely female, Caucasian, middle-aged participants.
As FMS continues to be a hardship for many U.S. residents, it also represents a
sizable burden in terms of health care costs (Cronan, Serber, & Walen, 2002). With
yearly medical costs of FMS being roughly 20 billion dollars, the average health care
expense for FMS patients can range between $2,274 and $4,417 (Cronan et al., 2002).

1

2

These health care expenditures appear to show steady growth, and they represent
a precise need for research into FMS symptom management.
Biological and psychosocial theories both struggle to account for the development
of FMS, but it appears likely that variables from both realms coalesce to produce FMS
(Laske et ah, 2007). Nevertheless, strictly biological and psychosocial theories have been
put forth by experts in various fields. Biological theories of FMS posit that
neurochemical and neuroanatomical abnormalities account for the pathogenesis of pain,
the most prominent FMS symptom (Kuchinad et al., 2007; Laske et ah, 2007; Arnold et
al., 2007; Crofford et al., 2005). These views are used to support the utilization of
pharmacotherapies to alleviate FMS symptoms such as pain and sleep disturbances
(Arnold et al., 2007; Crofford et al., 2005; Perahia, Pritchett, Desaiah, & Raskin, 2006;
Calandre, Morillas-Arques, Rodriguez-Lopez, Rico-Villademoros, & Hidalgo, 2007;
Tofferi, Jackson, & O’Malley, 2004). The use of medications has also been proposed as
being helpful for the improvement of FMS-related problems such as decreased quality of
life and depression (Bennett et al., 2005).
Psychosocial perspectives of FMS possess their own set of ideas regarding
causation. For example, given that FMS was first believed, and still is conceived in
various circles, to be psychosomatic in nature, psychological problems such as depression
and personality disorders have been identified as possible correlates (Bergman, 2005;
Sansone & Hawkins, 2004). Research on FMS treatments has also been abundant due to
the fact that psychosocial views as a whole tend to concentrate less on the causes of FMS
and work to formulate treatment plans for managing symptoms (Graven-Nielsen, 2000;
King et al., 2002; Raphael, Southall, Trehame, & Kitas, 2002).
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Depression appears to play an important role in FMS and has been estimated as
affecting as much as 10% of the elderly, medically ill population (Bosworth, Park,
McQuoid, Hays, & Steffens, 2003). This figure is likely generalizable to many people
who suffer from FMS because these patients are often middle aged or elderly (NIAMS,
1999; Goldenberg, 1987). Other research has also uncovered a strong link between FMS
and depression (Bosworth et ah, 2003; Perahia et ah, 2006; Tennen, Affleck, & Zautra,
2006). Hence, depression is included in this review as an important construct in need of
measurement in treatment studies.
A variable closely related to depression is catastrophizing. This construct
represents a negative coping response to pain, and it involves an attribution that the pain
experience itself is terrible and not capable of being handled (Williams & Gracely, 2007;
Gracely et ah, 2004). Catastrophizing has been studied in relation to how FMS patients
react to the experience of living with chronic pain. This discussion will review
interventions that have been found to produce changes in negative coping stances.
Another construct of interest to this discussion is quality of life. Since FMS can
profoundly affect not only physical but mental functioning as well, many FMS patients
experience decreased quality of life (Freedenfel, Murray, Fuchs, & Kiser, 2006; Turk,
Okifuji, Sinclair, & Starz, 1996). Current research has tried to address this need by
examining the role that psychosocial treatments can have in improving an individual’s
overall experience in dealing with FMS symptoms (Edinger et ah, 2005; Bernard, Edsall,
& Prince, 2000). It seems that an integral part of effective treatment programs is attention
to therapeutic strategies that can improve the overall quality of life for the participants.
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As biological and psychosocial theories for FMS treatments are advanced, it has
become necessary to seek a union of the two. A model incorporating the strengths of each
discipline could provide predictive power in determining useful treatments for FMS
symptoms. As such, this study will attempt to fuse together helpful concepts from both
biological and psychosocial theories in order to examine a comprehensive
biopsychosocial treatment model for FMS. This treatment model will be explained in
terms of how it could possibly improve the FMS-related variables of pain, depression,
catastrophizing, and quality of life.

Biomedical Causes
FMS is not an entirely new phenomenon. The FMS symptom of generalized,
unexplained pain was described as far back as the days of Hippocrates (Staud &
Domingo, 2001). The primary symptom of FMS, tender point pain, can be traced back as
far as 1824 (Goldenberg, 1987). Tender points represent pain due to hypersensitivity
when certain muscle tissues are palpated (Okifuji & Turk, 2002). They were originally
thought to be associated with rheumatism, but histological investigation by Stockman in
1904 disconfirmed this belief (Goldenberg, 1987). Additional symptoms added to the
FMS diagnosis eventually included generalized pain (aside from tender point pain),
fatigue, sleep disturbances, and an assortment of other symptoms (Goldenberg, 1987;
Arnold et ah, 2000; Nicassio, Schoenfeld-Smith et ah, 1997; Nicassio, Radojevic et ah,
1997; Bernard et ah, 2000).
Modem medical research has yet to account for the etiology of FMS (Henningsen,
Zimmerman, & Sattel, 2003), and this can only be regarded as further impetus for
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research. Several theories have been advanced as to the possible underlying biological
dysfunctions that drive FMS. These theories primarily have at their core the assumption
that physical causes are to blame for the development of FMS symptoms.
Wood (2006) argues that FMS pain is most likely caused by disruption of the
body’s nociceptive functioning. FMS pain is seen as the result of abnormal
oversensitivity in the central nervous system, specifically the hippomcampus. According
to this perspective, long-term potentiation of N-methyl-D-aspartate (NMDA) receptors
(central nervous system sensitization) occurs through excitatory synaptic messaging in
the spinal cord (Wood, 2006).
Sensitization of NMD A receptors represents a possible cause of FMS by
researchers who point out that ketamine, a non-competitive NMDA antagonist, has a
positive effect on chronic pain (Carr et ah, 2004). However, studies like these do not
provide strong support for Wood’s (2006) view that NMDA receptor dysfunction is due
to both lesions and chronic stressors. As has been noted by various researchers, lesions
may contribute to FMS symptoms, but there is no clear link between them (Nicholson,
2000; Arnold et ah, 2007).
Given the unclear relationship between lesions and FMS, Wood (2006) extends
his argument to include neurochemical dysfunction along with NMDA receptor
hypersensitivity as the possible root cause of FMS. Since emotions play a large part of
the pain experience, the limbic system is identified as a possible brain structure where
neurotransmitter dysfunction occurs. Dopamine is produced in the limbic system, and
there is evidence that ketamine, an analgesic with properties that have been inconsistently
shown to affect FMS pain (Cohen et ah, 2006), binds with D2 dopamine receptors more
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closely than with NMD A receptors (Wood, 2006). Wood thus advances a model that
places dopamine dysregulation as a possible cause of FMS symptoms (Wood et ah,
2007). He posits that FMS mimics Parkinson’s disease without noticeable motor deficits.
However, FMS does not result in dopamine degeneration as is Parkinson’s disease.
Despite this obvious difference, Wood maintains that dopamine dysfunction may drive
both disorders. This argument thus ushers in questions as to the level of genetic
heritability in FMS if dopamine dysfunction truly does produce FMS symptoms.
Thus far, genetic theories have not shed much light on the development of FMS
(Bergmann, 2005). Even though there appears to be a higher occurrence of FMS within
familial groups, recent twin studies has identified shared environmental factors as having
more weight than shared genetics (Bergmann, 2005). Other researchers have noted that
the increased heritability of depression may point to genetic influences for FMS due to
the high correlation that has been found between depression and FMS (Arnold et al.,
2004; Hudson & Pope, 1996), particularly in first-degree relatives (Nordahl & Stiles,
2007). This finding points to a complicated relationship between biological and
psychosocial factors that possibly form FMS symptoms. Such an integration will be
examined at a later point in this discussion.
Biological theorists have also been investigated the relationship between FMS
symptoms and entities such as serotonin and neurotrophic factors (Laske et al., 2007;
Patkar et al., 2007). Similarly to theories regarding the role of dopamine, ideas regarding
serotonin’s relationship to FMS involve the assumption that neurotransmitter dysfunction
contributes to abnormal pain processing (hypersensitivity, etc.).
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A specific serotonin receptor of interest in FMS research is the 5-HT3 receptor
(Barkhuizen, 2002). This receptor is responsible for modulating the release of substance
P and catecholamines. Since these neurotransmitters are known to affect the sensitivity of
pain processing in the brain, it may be that serotoninergic dysfunction may play an
unspecified role in FMS pain (Barkhuizen, 2002). Once again, however, there is the
question of how heritable these traits are in terms of genetic endowment across
generations. Recent reviews of evidence related to genetic contributions have theorized
that genetic factors tend to play a moderate and meaningful role in the expression of pain
perception and expression (Buskila, Neumann, & Press, 2005). Nevertheless, pain
experienced by individuals with familial histories of FMS is likely to be affected by
environmental factors as well (i.e. observed expression of pain by others, etc.).
Neurotransmitter dysregulation has been observed in FMS populations. By
working backwards to infer causation, biological research has attempted to investigate
whether certain classes of neurotransmitters may be to blame for particular FMS
symptoms. It seems as though the relationship between genetic factors and FMS pain
processing is not well understood at this time. Further research on genetic factors and
how they covary with environmental influences is needed. However, there is a large
amount of ongoing research investigating the medical treatments that can possibly
ameliorate certain types of FMS symptoms. Several of these proposed treatments will be
examined in order to shed light on the applicability of medical treatments to a syndrome
that has no clear pathophysiological etiology.
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Biomedical Treatments
Physical courses of treatment have undergone a couple historical shifts in regards
to FMS symptom management. For many years, FMS was inadequately treated through
various medications because there was little consensus as to what symptoms were
uniquely involved with FMS. It was not until 1990 that the American College of
Rheumatology outlined the key diagnostic criteria for FMS—widespread pain lasting at
least 3 months and pain in at least 11 of 18 tender point muscle tissue areas (Wolfe et ah,
1990). Other symptoms previously mentioned (sleep disturbances, fatigue, etc.) are
accepted as co-occurring secondary features of FMS. In more than a decade since this
formal diagnostic criteria was established, few studies found medical treatments to be
significantly effective for FMS (Arnold, et ah, 2000; Buskila, 2001; Bernard et ah, 2000).
Buskila’s (1999) review of psychopharmacological treatments reported few positive
effects with the use of drug therapy. The most prominent symptom of FMS, tender point
pain, seemed to show no improvement with the use of analgesics or sedatives. The only
FMS symptom that appeared to respond well to medications (sedatives, muscle relaxants,
and hypnotic agents) was sleep disturbance (Tofferi, Jackson, & O’Malley, 2004).
However, these findings were not considered very promising because they only affected a
less-common symptom of FMS.
A meta-analysis by Arnold et al. (2000) found that randomized, controlled trials
with anti-depressants such as tricyclics and selective serotonin/norepinephrine reuptake
inhibitors (SSRIs, SNRIs, respectively) were moderately effective in improving sleep
disturbances. Sleep disturbances were defined as any reduction in sleep quality as
reported by FMS patients. The researchers acknowledged that this finding was less than
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overwhelming because of the soporific effects these treatments were known to provide.
However, they also noted that tricyclic agents and SSRIs, in general, produced a small
effect on other FMS symptoms, including pain.
Encouraging findings regarding the possible utility of SSRI treatment with FMS
pain has spawned a wealth of research into this inquiry. Arnold and colleagues (2005)
examined the effectiveness of duloxetine hydrochloride (a combined SSRI and SNRI) on
FMS pain and overall health status. This well-designed study separated participants into
groups by dosage frequency (60 mg QD or BID) and by subgroups consisting of patients
with FMS and patients with combined FMS and depression. A path analysis of the
treatment effect found that duloxetine provided between a 2 to 2.5 point decrease in pain
severity on a 0-10 visual analogue scale (VAS) (Arnold et al., 2005). No significant
differences were found between groups with different dosage frequencies. Duloxetine
was also found to significantly reduce reported pain irrespective of a depression diagnosis
in FMS patients.
While the Arnold et al. (2005) study found a statistically and clinically significant
reduction in pain severity using duloxetine, a couple limitations were present. First, 90%
of the sample (N= 345) reported problems with various side effects (the most common
being dizziness), and 38% of the total sample withdrew from the study. Second,
participants were allowed to continue their regular use of over-the-counter pain
medications (aspirin, acetaminophen, etc). It is unknown what, if any, modulatory effects
these pain medications had concerning the introduction of duloxetine. Thus, this study’s
external validity was somewhat hampered by the inclusion of potentially spurious
variables and a moderate participant dropout rate.
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Other research into duloxetine’s effect on pain and depression has found similar
results as the Arnold et al. study (Perahia et ah, 2006). These authors reviewed structural
equation modeling of direct and indirect effects of duloxetine on both chronic pain and
depressive symptoms. They found that even though there is a relationship between
decreased depression and decreased pain, duloxetine provided about 50% of its pain
reduction through a direct analgesic effect (Perahia et ah, 2006). In patients with a
primary diagnosis of FMS, the researchers still found that duloxetine provided an effect
whether or not participants experienced depression. Thus, while it is likely that some of
duloxetine’s effect is due to its handling of depressed mood, it appears that it may also be
able to directly affect FMS pain in certain populations. These findings support the ideas
advanced by researchers such as Laske et al. (2007) who pointed out that
serotonin/norepinephrine dysregulation may contribute to FMS symptomatology.
A pharmacological treatment that follows the dopamine hypothesis put forth by
Wood (2006) is dopamine agonist therapy. Preliminary research regarding the proposed
utility of dopamine treatment seems to provide some reasonable support (Dadabhoy &
Clauw, 2006; Holman & Myers 2005).
Holman and Myers (2005) measured the effect of pramipexole, a second
generation DA3 (dopamine) receptor agonist, on reported FMS pain. Sixty participants
were randomly assigned to either a pramipexole or placebo group, and the study used a
double-blind method to measure changes in FMS pain, depression, and anxiety.
Participants in the treatment group demonstrated an average of 36% reduction in VAS
pain scores. This represented a statistically significant reduction in generalized pain over
the placebo group, that itself had a 9% average VAS score reduction. While generalized
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body pain was reduced (the first criteria for FMS), there was no statistically significant
reduction of tender point pain (the second FMS diagnostic criteria). Statistically
significant improvements included decreased fatigue and increased overall physical
functioning.
Though the findings by Holman and Myers (2005) showed about the same overall
effect as previous research on SSRIs, this study did not feature any dropouts from the
participant pool. Nevertheless, there were some definite concerns regarding drug
tolerability as every participant in the study reported at least one adverse side effect. The
most common side effects reported were weight gain in the placebo group and weight
loss in the treatment group. Nausea and increased anxiety also were common side effects.
Interestingly, there were no significant improvements in anxiety or depression reported.
This could possible speak to the specific effect that pramipexole had on pain and not on
the emotional processing of pain (depressed mood, etc.).
It appears from the study presented above that dopamine dysfunction may play a
role in causing FMS pain. However, given the findings that pramipexole affected only
one measure of FMS pain (generalized pain), there are likely more pathophysiological
mechanisms that affect the development of FMS besides dopamine. Ongoing research in
this area may provide further clarification, but it is clear that, at best, dopamine agonist
therapy only offers a partial solution to FMS symptoms.
Perhaps the most promising medication that has been studied with respect to FMS
pain is pregabalin (Zareba, 2005). This medication features analgesic, anxiolytic, and
anticonvulsant properties and shares structural similarity with gabapentin, another
commonly prescribed analgesic (Crofford et al., 2005). In a randomized, double-blind,
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placebo-controlled trial on the effectiveness of pregabalin, generalized FMS pain was
significantly reduced over an 8-week program of pregabalin use (450 mg QD) (Calandre,
Morillas-Arques et ah, 2007). The researchers also found that pregabalin produced
significant reduction of fatigue and sleep disturbances as well as significant improvement
in quality of life related to general health function. No effect on anxiety or depression
levels was discovered, which was not expected because of pregabalin’s history of being
prescribed for anxiety (Calandre, Morillas-Arques et al., 2007).
While pregabalin reduced generalized FMS pain about two points on a VAS, this
reduction represented less than a one-point improvement over the effect of placebo
(Crofford et al., 2005). The study by Calandre, Morillas-Arques and colleagues (2007)
also found a statistically significant effect when using a large dose (450 mg) of
pregabalin. However, the use of larger doses increased the frequency of adverse side
effects such as dizziness, sleepiness, weight gain, peripheral edema, and headaches.
Overall, 84% of the participants reported side effects.
Despite the promising claims of medications such as pregabalin regarding its
effects on FMS pain, fatigue, and sleep disturbances, treatment tolerability complications
are still evident. Thus, there appears to be a need for medically-based treatments that
provide viable outcomes with less side effect frequency and severity. Other medicallybased treatments that seek to accomplish this goal involve types of physical exercise and
homeopathic therapies that are aimed are reducing FMS symptoms. While these therapies
do not directly rely on pharmacologic pathways, they are still considered alternative
medicine strategies that can have measurable effects on FMS symptoms (Dadabhoy &
Clauw, 2006).
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A prevailing view of the relationship between physical fitness and FMS
symptoms is that deconditioning occurs as a response to increased pain and fatigue
(Pedersen & Saltin, 2006). As an FMS patient begins to avoid physical activity in order
to conserve energy and avoid pain, physical functioning continues to decrease. This
contributes to increased pain, and the cycle continues. Recently, researchers have pointed
out that FMS patients tend to have a significantly reduced capacity for oxygen recovery
and a decreased anaerobic threshold (Dinler et ah, 2007). This could indicate that FMS
patients experience markedly different barriers to physical exercise than people who are
not affected by this musculoskeletal diagnosis. However, it is unclear whether differences
in aerobic fitness are present in individuals before the development of FMS symptoms
later on in life. Thus, it is possible that fitness differences between FMS and non-FMS
populations may simply represent the co-occurrence of health degeneration that naturally
accompanies declines in regular physical activity (a noted part of the cycle described
above).
A large body of research exists regarding the relationship between physical
exercise and FMS symptom management (Pedersen & Saltin, 2006; Horwitz, Kowalski,
Theorell, & Andenberg, 2006; Burckhardt, 2005; Meyer & Lemley, 2000) and between
exercise and correlates of FMS symptoms such as depression and quality of life (Da
Costa, Dobkin, Drista, & Fitzcharles, 2001; Gowans et al., 2001; Oliver & Cronan,
2005). The general consensus of this literature is that physical fitness positively impacts
FMS symptoms of pain and fatigue while also bringing about some improvement in
mood alteration and increased quality of life.
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A longitudinal study by Havermark and Languis-Eklof (2006) measured the effect
of a physical therapy regimen on pain symptoms of FMS and the related variables of
anxiety, depression, and quality of life. The researchers recruited 375 participants to
attend a 10-week program of educational support groups that provided information about
a variety of physical exercises (water aerobics, stretching, etc.). After the program,
significant differences were found in pain, fatigue, and muscle stiffness. However, the
pre-post differences between scores (on a scale from 1-10) were less than a point for each
variable. Differences between anxiety and depression scores were nonsignificant. The
important finding from this study was that only one variable showed significant
improvement at posttest and after a period of 35 months—quality of life. Thus,
Havermark and Languis-Eklof suggest that the main strength of an exercise-based
program is that, while it may supply short term effects on physical functioning, it can
provide lasting outcomes with respect to increased quality of life.
A broad review of exercise-based interventions compiled by Pedersen and Saltin
(2006) found that tender point pain was significantly decreased by 28% after aerobic
exercise. Other commonly-reported physical improvements in exercise-based research
studies include decreased fatigue, muscle stiffness, and generalized body pain. An
important feature of these treatments is that exercise is more effective when supervised
by qualified physical therapists and when patient education is provided in tandem with
exercise training. Additionally, there appears to be little added benefit in increasing the
intensity of physical exercise. Low-impact physical exercises such as warm-pool aerobics
and hydrotherapy seem to substantially alleviate pain symptoms without the risk of injury
(Mannerkorpi & Card, 2003). These types of interventions may also be useful for other
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FMS-related problems such as sleep disturbances and low quality of life as well (de Melo
Vitorino, de Carvalho, & do Prado, 2006; Tomas-Carus et ah, 2007).
As has been discussed, it appears that pharmacological and nonpharmacological
medical treatments may offer varying levels of efficacy in relieving FMS symptoms and
related problems (depression, quality of life, etc.). While there is a growing body of
literature involving the use of SSRI/SNRIs, dopamine agonists, and anticonvulsants, no
one medication appears to provide a persuasive cure for FMS symptoms (Vitton,
Gendreau, Gendreau, Kranzler, & Rao, 2004). Also, recent pharmacological research
suggests that, due to the commonality of adverse side effects, there may be serious
concerns with relying completely on medication-based treatments for FMS. Despite this
problem, recent advances in medical treatments have shown some reasonable
effectiveness in pain reduction (Baker & Barkhuizen, 2006; Calandre, Hidalgo, & RicoVillademoros, 2007).
Another area of research has examined the effect of exercise on FMS symptoms
and related problems such as depression and quality of life. Exercise appears to offer
mild decreases in physical symptoms and moderate improvements in quality of life and
mood difficulties as well (Yeung & Hemsley, 1998; Rudolph & Kim, 1996; Yeung, 1996;
Gowans, et ah, 2001), Exercise-based interventions are less prone to feature harmful side
effects (especially when appropriate training and supervision of treatment is provided),
plus they seem capable of offering some lasting effects even after discontinuation of the
treatment program. Thus, it seems that exercise training may be especially useful when
combined with other treatment components as part of a comprehensive program for FMS
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symptom management. Other types of interventions that could possibly constitute a part
of such a treatment scheme will be examined later in this discussion.

Psychosocial Causes
Just as biomedical theories have been advanced regarding FMS etiology,
perspectives about the role of psychosocial causation have also been considered.
Research has implicated a relationship between psychopathology and FMS diagnosis
(Hallberg & Carlsson, 2000). Proponents of this view point out that chronic pain patients
in general display many different psychopathological disorders (Herken, Giirsoy, Yitkin,
Virit, & Esgy, 2001; Deardorff, 2000). Others point out, however, that the psychological
determinants of FMS do not preclude the very real idiographic sensation of pain that
FMS sufferers may feel (Rubin, 2005). One problem with perspectives involving
personality or psychopathology constellations in FMS populations is that they do not fall
neatly into either a medical or a psychological category. Nevertheless, this ambiguity
does not diminish the need for examining the complex relationship between
psychopathology and FMS. Another psychosocial hypothesis to be reviewed has spawned
significant research and regards the possibility that traumatic events (physical, sexual
abuse, etc.) are predictive of later FMS symptoms (Walker et ah, 1997; Ciccone, Elliot,
Chandler, Nayak, & Raphael, 2005).
A common sentiment that still prevails in some circles of modem medicine is that
FMS is a “fashionable diagnosis” that masks psychopathology and is the product of
somatization (Ford, 1997, p. 7; Davidson III, 2003). This assumption seems to have been
reinforced in the medical community now that some level of symptom relief is being seen
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with the use of psychoactive medications (North, Hong, & Alpers, 2007). Unexplained
somatic complaints have been estimated as being one of the leading causes of outpatient
hospital visits (Kroenke, 2003), and higher levels of somatization in FMS populations
have been noted in cross-cultural studies as well (Herken et ah, 2001). In terms of the
association between somatization and FMS symptoms, there seems to be some evidence
that higher rates of somatic complaints tend to precede later development of FMS
diagnosis (McBeth, MacFarlane, Benjamin, & Silman, 2001; Gupta et al., 2007; Rubin,
2005).
Gupta and colleagues (2007) conducted a study that specifically examined the
FMS diagnostic criterion of generalized pain, also known as chronic widespread pain
(CWP). The authors used a population-based prospective approach to measure health
anxiety, depression, sleep problems, and frequency of somatic complaints in 3,171
participants that showed no evidence of CWP at baseline. These participants were then
assessed after 15 months in order to determine differences between those who had
developed CWP and those who did not.
This research study found that participants who listed somatic complaints were
2.2 times more likely to develop CWP at follow-up (Gupta et al., 2007). Participants who
reported high scores on more than one particular variable (i.e. health anxiety plus somatic
complaints, etc.) were 6 times more like to experience CWP. When participants scored
highly on the three factors of somatic complaints, sleep problems and health anxiety, they
were 12 times more likely to encounter later difficulties with CWP. These findings
illuminate a possible relationship between somatization and FMS symptomatology.
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The outcomes discovered by Gupta et al. (2007) could possibly be interpreted as
providing support for not only the link between somatization and FMS but for general
mental illness problems (anxiety, depression, personality disorders, etc.) and FMS
(Winfield, 2001). While it is important to keep in mind that the Gupta et al. study isolated
somatic complaints as the strongest predictor of CWP, predictive power was still
demonstrated by other psychological variables as well. Furthermore, a relationship
between somatization and FMS does not indicate that symptoms are purposely
malingered. Research in FMS populations has shown that even patients who reported
high levels of pain and depression showed no evidence of symptom fabrication using the
Test of Memory Malingering (TOMM) (Iverson, Le Page, Koehler, Shojania, & Badii,
2007).

A definite strength of the Gupta et al. (2007) research was that it managed to
study the temporal progression of psychological and physical difficulties through the use
of a longitudinal design. However, the authors were not able to designate CWP
development in patients with solely psychological problems as opposed to participants
who may have had underlying medical reasons for the genesis of CWP. The research also
used a relatively short follow-up time (15 months) that precluded the authors from
examining long-standing personality traits in relation to pain experience. Neither was any
attempt made to measure the relation of psychosocial events such as abuse history to later
CWP. Studies aimed at investigating these two hypotheses will now be examined.
Research has been carried out on the relationship between FMS and constructs
such as a depressive personality type (Nordahl & Stiles, 2007). These researchers
compared depressive symptomatology in an FMS group versus a group with Major
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Depressive Disorder (MDD). Their analysis uncovered specific differences within the
FMS group. FMS patients who had no prior history of depression showed no differences
in depressive cognitive distortions when compared to a healthy control group. However,
FMS patients with any history of depression were more likely to have cognitive
distortions similar to the MDD group. While these results seem rather intuitive, they also
seem to support the notion that elevated depression levels in FMS patients do not
necessarily denote a depressive personality.
A study that examined the link between borderline personality disorder (BPD)
and FMS conducted interviews with patients who currently met criteria for BPD and
patients who no longer met criteria (designated as “remitted borderline patients”)
(Frankenburg & Zanarini, 2004, p. 1661). Remitted borderline patients were found to be
significantly less likely to experience FMS symptoms than patients with a current
diagnosis of BPD. The authors pointed out that BPD patients featuring stronger disorder
severity (hence, non-remitted) were more likely to have FMS. This argument was clearly
cloaked in the assumption that FMS is strongly attributable to psychopathology.
However, no clear temporal relationship was established between time of BPD diagnosis
and FMS diagnosis. Thus, it is difficult to know whether BPD could serve as a cause of
FMS or as a type of co-morbid disorder as seems to be the case with depression.
Recent theoretical perspectives on personality and genetic-level causation has
started to categorize these factors as “vulnerabilities” rather than direct determinants
because of their loose, yet viable, relationship to later problems (Brown, in press). The
idea of personality disorders (BPD) as causative of FMS seems to be weakened by more
recent research that shows BPD patients are actually more likely to show very different

20

pain thresholds than are commonly reported by FMS patients (Jochims, Ludascher,
Bohus, Treede, & Schmahl, 2006).
While it seems clear that psychopathology in general is over-represented in FMS
populations, no clear arguments have been put forth regarding how pathology is actually
driving, rather than co-occurring with, FMS (Hallberg & Carlsson, 2000). Another
hypothesis that struggles with this very question relates to the role of trauma or abuse in
predicating FMS (Rubin, 2005). Research suggestive of this relationship is sparse yet
intriguing.
A recently-developed perspective regarding how FMS progresses involves the
relationship between traumatic events (physical, sexual abuse) and FMS (Brown, in
press). As mentioned earlier, this is a view that substantially draws from the cross
discipline research—notably medicine (neurobiology) and psychology. Research by
Ciccone et al. (2005) found that FMS patients were significantly more likely to report
traumatic abuse (rape, etc.) than healthy controls. In this retrospective study, FMS
participants with an abuse history reported at least a five year delay between traumatic
events and the commencement of unexplained pain. While this satisfies the temporal
requirement for trauma to act as a cause, little information was available regarding other
physical events that might have also precipitated FMS pain. Thus, it could be that
psychosocial causes (emotional reactions to abuse, stress, etc.) contributed to later FMS
along with other physical determinants such as neurobiological and physical correlates of
trauma.
One study skeptical of the abuse hypothesis found that some physical injuries are
more predictive of FMS pain than others (Staud & Domingo, 2001). These authors state
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that the relationship between trauma and FMS is an availability heuristic that erroneously
links abuse with FMS. Even researchers who have found tentative relationships between
abuse history and FMS point out that sampling errors and lack of specificity in abuse
terminology severely limits the applicability of the abuse hypothesis.
Research into the causative properties of somatization, personality disorders, and
abuse history all provide a unique view of how FMS may develop. There is currently no
clearly-defined process as to how these psychosocial causes may be linked with FMS.
However, research has uncovered interesting findings regarding the peculiar aggregations
of psychological symptoms along with unexplained FMS pain. It seems unlikely that
FMS patients are consciously malingering their symptoms, and they appear be
encountering a phenomenon that is very real to their psychophysical experience. Further
research into the mysterious co-occurrence of psychopathology and prior abuse histories
of FMS patients is needed for added insights into psychosocial causation.

Psychosocial Treatments
Having reviewed various biological and psychosocial theories of FMS
causation, it seems apparent that no one perspective currently offers a comprehensive yet
parsimonious explanation of how FMS can be treated. Presently, treatment interventions
for FMS are focused on symptom management because of a lack of treatments
efficacious in reversing the action of this syndrome (Lemstra & Olszynski, 2005).
Nevertheless, symptom management still provides a hefty task for clinical interventions
because of the sheer number of symptoms and related problems that can be present with
an FMS diagnosis. Once again, this discussion will review promising interventions—in
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this case, psychosocial interventions—that have shown some efficacy causing changes in
FMS pain, depression, catastrophizing coping styles, and overall quality of life. It is
important to keep in mind that since current interventions must focus on symptom-level
problems, associated features of FMS (i.e. depression, negative coping styles, etc.) are
necessary targets of psychosocial treatments as well. This broad focus assumes that wideranging, holistic approaches for managing FMS allow for the treatment of multiple facets
of the nebulous collection of FMS symptoms and related features (Fawcett, 2005). After
reviewing FMS treatments that target the aforementioned variables, factors that may
drive these interventions work will be examined. These process variables are social
support and common therapeutic factors.
Multidisciplinary treatment strategies for managing FMS have recently begun to
receive increased attention in FMS literature. However, these types of treatments have
typically shown little effect in terms of actual pain reduction in FMS populations
(Lemstra & Olszynski, 2005). Instead, multidisciplinary studies have tended to show
improvements with depression levels and quality of life. Lemstra and Olszynski (2005)
conducted a study that featured the implementation of psychoeducational groups in order
to provide participants with information about FMS, facilitate stress management
training, and help develop an exercise regimen. These groups (treatment and control)
were conducted for a six week period before measuring changes in several variables such
as depression, pain intensity, and change in health status. Follow-up measures of these
variables were also given 15 weeks after the completion of the groups.
The results of the study were that patients receiving the psychoeducational
intervention reported a significantly decreased level of depressed mood than controls
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after six weeks of treatment (Lemstra & Olszynski, 2005). Interestingly, the authors also
found that pain severity was significantly reduced after the six week intervention and at a
15 month follow up. This effect is probably most attributable to the treatment component
of light physical exercise that the authors utilized. The researchers stressed that such
benefits are most likely due to the high motivation of patients in adhering to the treatment
protocol by following through on the prescribed exercises.
Though the findings of Lemstra and Olszynski (2005) seem to support the
positive effect that multidisciplinary psychosocial treatments can have on FMS without
the inclusion of medications, there were some key limitations that must also be
considered. First, a common feature psychoeducational studies like this one precludes
them from being able to blind participants from knowing whether or not they are
receiving the intervention. Thus, the increased attention from being in the treatment
group could possibly generate an exaggerated effect of the treatment’s efficacy (the
Hawthorne effect). Second, the authors did not screen for or exclude patients with other
rheumatological or psychiatric comorbidities. Thus, it is not clear whether their
intervention was truly specific to FMS patients or whether the treatment was having an
effect on problems related to other diagnoses (i.e. chronic back pain, major depression,
etc.).
Despite the limitations listed above, it seems as though there is some evidence
for the utility of psychosocial treatments that include interventions from a wide variety of
disciplines. A meta-analysis by Sim and Adams (2002) also found that psychosocial
treatments featuring stress management and light physical exercise tended to have good
effects on depression. While Sim and Adams point out that the use of multiple disciplines
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(physical therapy, psychology, etc.) clouds the ability to detect specific change agents in
FMS symptoms, there also seems to be an overall tendency for statistical significance to
be depressed as a result of low N designs and decreased power. Therefore, the researchers
argue that these studies may actually provide conservative estimates of their true
treatment efficacy. Also, it seems as though the clinical significance of these
psychosocial studies is helpful to keep in mind and should not be diminished as a result
of depressed statistical significance.
A particular feature of multidisciplinary treatments that has been found to be
effective in FMS symptom management is cognitive-behavioral therapy (CBT). In
response to Bradley’s (1998) call for research into psychological treatments for FMS,
many studies have found that CBT interventions have positive effects on depression
(Hooten et al, 2007; Bums, Johnson, Mahoney, Devine, & Pawl, 1998). Bums et al.
found that group and individual CBT therapy, coupled once again with exercise,
produced significant pre/post decreases in both pain and depression. The findings related
to depression were of particular interest because the authors also discovered that personal
feelings of helplessness decreased. Thus, they postulated that the CBT intervention
caused a shift in patients’ self-defeating attitudes as well as concomitant depressed
feelings.
Negative associated features of FMS include both depression and
catastrophizing, and these are also commonly found in relation to chronic illnesses
(Nicassio et al., 1995; Burckhardt et al., 1993; Turner, Jensen, Warms, & Cardenas,
2002; Turner, Jensen, & Romano, 2000; Kashikar-Zuck et al., 2002; Gracely et al., 2004;
Keefe et al., 2000; Arnold et al., 2004). While it may appear that the experience of pain
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being associated with depression and catastrophizing is obvious, the relationship of these
two constructs to pain-related outcomes is important to clearly delineate.
Catastrophizing is defined as an individual’s counterproductive response to pain
“as being awful, horrible and unbearable” (Gracely et ah, 2004, p. 836), and it is evident
when a person worries excessively about impending problems (Turner et ah, 2000).
Catastrophizing is a part of the coping process where problems are identified as threats.
Lazarus and Folkman (1984) argue that an early phase of the coping response involves
appraising events in terms of their particular import on the individual. According to this
oft-cited view, primary appraisals are the cognitive actions undertaken by individuals to
evaluate meaningful life events (Lazarus & Folkman, 1984). The three possible
appraisals are irrelevant, benign-positive, and stressful. Stressful appraisals are of interest
here because these are thought to tie directly to the process of coping. The three
subcategories of stress appraisals include harm/loss, threat, or challenge appraisal.
Harm/loss and threat appraisals denote that a person has already sustained or is about to
sustain imminent losses due to the stressful event (Lazarus & Folkman, 1984).
Catastrophizing appears to function as a primary appraisal that constricts an FMS
patient’s ability to maintain a sense of control and cope adequately with symptoms.
Lazarus and Folkman (1984) also describe the concept of secondary appraisals.
These appraisals go beyond the appraisal of an event as stressful. Once a person has
designated that a situation or problem is a stressor, he/she must then cognitively assess
his/her perceived efficacy in solving the presenting problem (Lazarus & Folkman, 1984).
Using this logic, catastrophizing may serve as a primary appraisal that affects whether or
not an individual believes they have the resources and abilities to actively cope with
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problems or passively avoid them. Problem-focused coping is a term used to denote the
formation of actual solutions to problems once they have been thoroughly assessed.
Emotion-focused coping signifies the reduction of emotional distress through various
forms of self-regulating cognitive actions (Lazarus & Folkman, 1984). Based on these
definitions, it appears that catastrophizing may be more likely to produce emotional
distress and precede the use of emotion-focused coping.
While catastrophizing and depression seem like closely related constructs,
research has shown that both depression and catastrophizing explain meaningful variance
in outcomes related to chronic pain illnesses (Osborne, Jensen, Ehde, Hanley, & Kraft,
2007; Turner, et ah, 2002; Turner, et ah, 2000; Keefe et ah, 2000). Catastrophizing has
also been found to be a coping style present in FMS patients with or without a history of
depression (Tennen, Affleck, & Zautra, 2006). Another study conducted by Turner et al.
(2002) examined how catastrophizing affected adjustment to chronic pain. The
researchers used the Coping Strategies Questionnaire (CSQ), a scale whose psychometric
properties have been thoroughly examined. Turner et al. (2002) found that increased
catastrophizing predicted poorer adjustment to chronic pain.
Even though catastrophizing is apparent in other chronic illness populations,
research on FMS patients has uncovered a significantly higher rate of catastrophizing
than in patients with other musculoskeletal diagnoses (Marley, Boyd, Bacchus, &
Katsaros, 2007; Mellegard, Grossi, & Soares, 2001; Hallberg & Carlsson, 2000).
Mellegard et al. found that FMS patients were more likely to construe their experience as
hopeless and rely on fantastic hopes of miracle cures. FMS patients also seem more likely
to catastrophize and experience concomitant decreases in health functioning than do
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individuals with other musculoskeletal disorders such as rheumatoid arthritis (Marley, et
ah, 2007). Catastrophizing appears to contribute to increased levels of reported pain and
depression. Therefore, it seems as though a useful target for a psychosocial FMS
treatment would be to decrease negative coping such as catastrophizing in order to
generate improvements in other areas of functioning as well (i.e. possibly decreased pain
and depression).
Given the prominence of poor coping styles in FMS populations, newer research
on psychosocial interventions has also been geared to effect changes in catastrophizing
(Hooten et al., 2007). Hooten et al. used a brief three week series of pain management
interventions that included CBT group sessions, relaxation training, exercise, and general
health education. At the end of this treatment, patients demonstrated a statistically
significant reduction on the CSQ catastrophizing subscale. The difference found between
pre-treatment and post-treatment scores was approximately one standard deviation. This
difference was enough to reach statistical significance, and it also represented a clinically
significant reduction of pain-related negative coping. Catastrophizing has been linked
with increased pain, reduced physical functioning, and psychological problems such as
depression. The findings by Hooten et al. represent a useful change in catastrophizing
that can logically have a positive impact on a host of other pain-related variables
(Osborne et al., 2007).
A decided weakness of the Hooten et al. (2007) study, however, was that there
was no control group. Since the researchers did not examine the presence of
catastrophizing in a population of FMS patients who did not receive the treatment, it is
not completely clear whether the treatment effect was derived as a result of the
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intervention or another variable such as passage of time, etc. Also, while the authors
found a statistically significant effect for their treatment after three weeks, they neglected
to complete any follow up assessment on whether or not these gains tapered off, were
maintained, or even resulted in increased functioning over time.
Notwithstanding the weaknesses of the Hooten et al. (2007) study, this research
represents one of the few examples where catastrophizing was measured in relation to
actual changes as a result of treatment. Most literature on this construct has been limited
to examining catastrophizing in other chronic pain populations and describing what it is
not, rather than how it can be effectively treated. Thus, Hooten and colleagues have
greatly contributed to the understanding of how catastrophizing may actually be reduced
in an FMS population. Considering the dearth of research on effective methods for
reducing catastrophizing, especially with regard to FMS patients, it appears that this
problematic concept is in need of being more adequately investigated, especially from a
clinical vantage point.
A couple other research studies have provided glimpses into how catastrophizing
can be targeted as part of a treatment study (Spinhoven, et al., 2004; Smeets, Vlaeyen,
Kester, & Knotterus, 2007). Though these studies did not implement their treatment
strategies on FMS patients, they have still managed to seek out populations that are
closely related (i.e. chronic back pain, etc.). For example, Smeets et al. examined the
separate and combined effects of physical activity and CBT on catastrophizing in patients
with “nonspecific chronic low back pain” (Smeets et al., 2007, pg. 216). This study
divided the 211 participants into four groups: physical activity, CBT, combined (physical
activity + CBT) and control. The results of this study were that all three treatment groups
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demonstrated statistically significant reductions in catastrophizing, but no such change
was present in the control group. Additionally, catastrophizing was found to mediate
depression decreases in the physical activity alone group. This once again speaks to the
meaningful difference between the two constructs of catastrophizing and depression.
Smeets et al. (2007) used their findings to argue that, even though all three groups
had significantly reduced levels of catatrophizing, it is likely advantageous to use
treatment approaches that offer integrative, multidisciplinary strategies (cognitive,
behavioral, physical, etc.). This provides unique support to research studies such as
Hooten et al. (2007) that did not separate out the specific treatment effects generated by
their inclusive approach to FMS intervention.
The last treatment variable to be reviewed with respect to psychosocial treatments
of FMS is quality of life. This construct is indeed quite broad and typically described in
relation to FMS as involving body pain, overall physical functioning (including ease of
performing activities of daily living), general health, psychosocial well-being, and
emotional functioning (Reisine, Fifield, Walsh, & Dauser, 2004; Lindberg & Iwarsson,
2002; Gur, Cevik, Nas, Sarac, & Ozen, 2006; Bernard et al., 2000). While quality of life
appears to be a heterogeneous concept, it is accepted as being a variable that tends to
negatively correlate with FMS symptomatology.
Quality of life has been found to be strongly related to decreased physical
functioning in FMS populations (Reisine et al., 2004). Reisine and colleagues stated that
FMS patients are 40 times more likely to report lower quality of life than healthy
controls. The authors compared FMS patients and health controls (Ns in each group
equaled 287 and 286, respectively), and their sample of FMS patients was representative
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of the types of people who have been found to report higher incidences of FMS. These
populations are typically middle-class SES, female, and middle-aged (47 being the mean
age in this study). Theadom, Cropley, and Humphrey (2007) similarly found that quality
of life for FMS patients is lower than what is normally reported in community samples.
These authors suggest that a possible way to provide increases in quality of life may be to
focus on psychosocial interventions related to sleep hygiene. Theadom et al. measured
quality of life in 99 FMS patients who also reported decreased sleep quality. Poor sleep
quality was found to be a strong predictor of low quality of life. Thus, there may be a
need for sleep hygiene treatment along with other psychosocial interventions that might
produce quality of life benefits for FMS patients.
One study that specifically investigated the usefulness of a psychosocial sleep
hygiene intervention was conducted by Edinger et al. (2005). The authors did a
commendable job of measuring an informational sleep hygiene intervention as well as a
CBT intervention for FMS patients with insomnia. This study found that no significant
wakefulness reduction was apparent in the control group. Both the sleep hygiene and the
CBT group were found to experience a statistically significant reduction in nighttime
wakefulness, but the CBT group’s percentage of wakefulness reduction was more than
twice that of the sleep hygiene group. It may be that CBT interventions specifically
aimed at insomnia may be a better option than sharing sleep hygiene information alone.
In terms of quality of life, the CBT group in the Edinger et al.(2005) study
demonstrated significant improvement—^benefits that once again were larger than the
statistically significant improvement of quality of life in the sleep hygiene group. From
this study’s findings, it seems as though psychosocial interventions including CBT and
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sleep hygiene psychoeducation can be useful for positively impacting FMS related
variables, including quality of life. However, CBT may provide the greater benefit
(Richardson & Richardson, 1999).
Another study based on the strong support found in the literature concerning the
relationship between FMS and decreased quality of life, discovered that information
sharing interventions coupled with physical exercise can be a useful approach for
increasing quality of life in FMS populations (van Wilgen, Bloten, & Oeseberg, 2007).
Similarly to studies that incorporated exercise-alone interventions, this recent study found
that a psychosocial treatment program (general information about FMS and group
discussion) combined with physical exercise produced statistically significant increases
in quality of life. The research used a time series design but lacked a control group. The
results of this study are still striking, however, because these statistically significant
quality of life improvements were found after instituting the treatment program in a
primary care setting. It has been noted that some treatment programs, while providing
effective symptom management for FMS, can incur significant financial burdens
(Zijlstra, Braakman-Jansen, Taal, Rasker, & van de Laar, 2007). Thus, the encouraging
findings of van Wilgen et al. also seem to indicate that psychosocial interventions may
allow for convenient and even cost-effective options for FMS treatment.
The studies reviewed thus far have found convincing evidence that psychosocial
treatments, though occasionally combined with biomedical (exercise) treatments, can
provide definite improvements in quality of life for FMS patients. Other research
endeavors have identified psychosocial interventions as being strongly predictive of
quality of life change in other populations (e.g., Verbeek, Konings, Aldenkamp,
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Declerck, & Clip, 2006). However, studies such as these have isolated psychosocial
treatment effects in populations separate from, albeit related to, FMS. While there are few
studies that measure the effect of purely psychosocial interventions on quality of life in
FMS populations, the future of these interventions appears promising.
An important issue germane to the effectiveness of psychosocial interventions is
the concept of process variables. There is research evidence that psychosocial treatments
can positively affect variables such as pain, depression, coping styles, and quality of life.
However, these findings naturally lead to questions about what sorts of mechanisms or
processes are functioning to cause these outcomes. Such processes vary in terms of their
difficulty of being measured, but they do make it easier to make theoretical sense of how
certain causes (physical and psychosocial interventions) can produce outcomes (changes
in FMS symptomatology and related variables). Foremost among these is social support.
Social support is a powerful feature of psychosocial treatments that has been
strongly upheld in the FMS literature (Franks, Cronan, & Oliver, 2004; Lofgren, Ekholm,
& Ohman, 2006). Franks and colleagues used a large sample (N= 568) to examine
whether social support predicted changes in physical and/or psychosocial aspects of
FMS. Using multiple regression, these researchers found that higher reported satisfaction
with one’s social support network predicted increased psychological well-being and
decreased depression. Increased self-efficacy was also found to be a function of having a
larger number of social support contacts. This speaks to both the necessary quantity and
quality of social support. However, Franks et al. opine that, of the two, satisfaction with
social support quality is more predictive of positive psychosocial outcomes than sheer
number of social contacts alone.
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An insightful study carried out by Bigatti and Cronan (2002) uncovered a
troubling wrinkle concerning social support and FMS. Aside from the well-documented
impact that FMS can have on the patient him/herself, there is evidence to suggest that
FMS is also correlated with poorer physical and mental health in spouses/domestic
partners. This sample consisted of 135 couples where the female member was diagnosed
with FMS. When compared against males with non-FMS wives (N= 153), husbands from
FMS dyads reported significantly higher levels of depression, fatigue, loneliness, and
subjective stress. Qualitative analysis of these differences found that husbands of FMS
patients reported having to make significant lifestyle changes in order to accommodate
the needs of their wives. This appears to clarify the finding that FMS patients who
reported fewer depressive symptoms were married to partners who experienced more
psychological problems. Thus, it could be that FMS patients in this study were deriving
necessary social support from their husbands but that the husbands themselves could not
adequately cope with their own stress levels.
These results point to the complexity of concepts such as social support, but they
do not mean that spouses and family members of FMS patients bear negative
psychological consequences alone. Indeed, it seems as though the entire family unit can
be affected by the strain of an FMS diagnosis (Preece & Sandberg, 2005). An increase in
family strain has been shown to positively correlate with increased FMS symptom impact
on individuals. Conversely, there also appears to be a general increase in FMS patients’
ability to cope when they are part of a resilient family support network. Therefore, social
support appears to serve a helpful function when it is characterized by meaningful,
resilient relationships. Flowever, negative patterns of handling family strain can have a
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detrimental impact on an FMS patient’s ability to cope with and effect changes in their
symptomatology (Murray, Daniels, & Murray, 2006).
Along with social support, another variable that may serve to enhance
psychosocial interventions is the perception that the information shared is valuable and
effective. Thus, it could be that the patient’s awareness of a particular symptom
management strategy or coping response may serve to produce desired effects (Lindberg
& Iwarsson, 2002). This has also been described as a “psychotherapy placebo effect”
(Wampold, Minami, Tierney, Baskin, & Bhati, 2005, p. 850). While this continues to be a
controversial topic in psychotherapy research, a contemporary view is put forth by
Lambert (2005). The term “placebo” can be replaced by the construct of “common
factors” that contribute to therapy outcomes. From the perspective of the psychosocial
interventions heretofore elucidated, common factors could be used to explain how
treatment effects may be due to attributions patients make about the helpfulness of the
material presented. Common factors could also possibly represent the therapeutic effect
that can be derived from receiving information from a reliable or respected source (i.e. an
FMS patient’s physician, etc.).
Process variables appear to have potential for causing the effect of psychosocial
interventions on FMS symptoms and related variables. Both social support and common
therapeutic factors seem to function as mechanisms of change. Psychosocial interventions
have been discussed regarding their usefulness in managing FMS symptoms such as pain
and sleep disturbances. Variables commonly found to co-occur in FMS patients
(decreased quality of life, depression, and catastrophizing coping styles) all appear to be
capable of being affected by integrative psychosocial interventions. There does not
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appear to be any consensus in the literature about the exact combination of psychosocial
interventions needed to produce a maximum effect on FMS symptomatology (Carville et
ah, in press). However, it seems likely that certain psychosocial interventions (CBT,
presenting education related to FMS, etc.) may provide positive effects on FMS
symptoms and even on several of the related problems that tend to accompany this
diagnosis (Morris, Bowen, & Morris, 2005; Fawcett, 2005; Goldenberg, Burckhardt, &
Crofford, 2004; Borg-Stein, 2006).

Biopsychosocial Considerations
Thus far, this discussion has reviewed contrasting viewpoints regarding etiology
and treatment of FMS. Biomedical contributions have portrayed FMS as having an
etiology largely driven by biological causes (Figure 1).

Genetic contributions
Neurochemical Dysfunction

FMS

Neuroanatomical abnormalities
Figure 1. Biomedical Theories of FMS Etiology

Biomedical theories of FMS are characterized by a unidimensional view of
etiology that explores linear, physiological pathways by which a disease or syndrome can
possibly progress (Turk & Okifuji, 2002). An assumption of the biomedical model is that
all phenomena must be reduced to their lowest possible substrates before having any
explanatory power. Thus, person-level variables, such as cognitions, that do not neatly
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fall on either side of a dualistic mind-body split are not accounted for in the model.
Purely biological theories of FMS causation seems to be sparse, but the high volume of
research being carried out on medication-based treatment is indicative of the pervading
belief that medical causes may be most responsible for the development of FMS (Wood,
2007; Williams & Gracely, 2007).
At a time when FMS symptoms were being evaluated in order to form a
diagnosis, Goldenberg (1987) wrote that the lack of a clear biomedical etiology for FMS
meant that it was usually conceptualized as a “psychogenic rheumatism” (p. 2784).
Interestingly, this sentiment supported a decidedly psychosocial etiology of FMS because
agents such as nonspecific psychopathology and high stress levels were seen as primary
causes (Figure 2). It now seems that such an extreme view may be just as theoretically
limiting as a purely biomedical model is as well.

Psychopathology
Increased Stress

>

FMS

Personality Traits
Figure 2. Psychosocial Theories of FMS

A theory that integrates both biomedical and psychosocial forces is the
biopsychosocial model (Engel, 1980). It is important to realize that the biopsychosocial
model was not developed specifically for FMS or any particular diagnosis. Rather, it
explains the necessity of studying the ways by which person-related variables can
account for differences in health issues. Essentially, the biopsychosocial model allows for
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interactions between all variables even on different levels of analysis (Figure 3). This is
an important feature of the biopsychosocial model because it explains why single
variable causes are commonly found to explain only a small portion of the variance in
FMS symptom outcomes.
Nearly a quarter century later, Ray (2004) added his support to this model by
noting how social variables account for wide differences in illness and even mortality.
Ray highlights the usefulness of the biopsychosocial model by arguing that, just as
physical causes in brain function alter thoughts, so too do cognitions have the capacity to
affect brain development and overall physical functioning. Thus, biomedical entities are
construed as not only causing unique variance in observed phenomena, they also can alter
the relationship between psychosocial causes and observed phenomena (and vice versa).

Biomedical causes
FMS

Psychosocial causes

Figure 3. Biopsychosocial Model of Causation

In recent years, the biopsychosocial model has been increasingly used in order to
explain individual functioning within the context of illness (Brown, in press). The
theoretical work of Ray (2004) and Engel (1980) seem to allow for biomedical treatments
as well as person-level variables (i.e., information gathering, CBT, etc.) to cause changes
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in observed phenomena such as FMS. Application of the biopsychosocial model in terms
of FMS may increase understanding of the various forces that can develop, maintain, and
possibly help treat FMS. Given the research reviewed thus far concerning specific
variables and their categorization as either biomedical or psychosocial in nature, Figure 4
illustrates possible components of a treatment-oriented biopsychosocial model for FMS.

Biomedical Treatments
(medications, exercise)
Decreased FMS pain, depression, and
catastrophizing; increased quality of life

Psychosocial treatments
(Information, CBT)

Figure 4. Biopsychosocial Model for FMS Treatment

Hypotheses
This discussion has attempted to elucidate the complex relationship that exists
between both biomedical and psychosocial forces and FMS. FMS appears to most likely
be the product of both medical (Kuchinad et al., 2007; Laske et al., 2007; Arnold et al.,
2007; Crofford et al., 2005) and psychosocial causes (Bergman, 2005; Sansone &
Hawkins, 2004). Both perspectives have also put forth strong arguments in terms of their
respective theory-based contributions for treatment modalities. These treatment
suggestions have been examined regarding their posited effect on FMS symptoms and
related variables such as depression, catastrophizing, and quality of life. The
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biopsychosocial model has been reviewed as a theoretical system that allows for both
person-level and biologically-based variables to affect phenomena of unknown origins.
From a biopsychosocial perspective, it can be reasonably suspected that the most
effective treatments for FMS symptoms and related conditions may draw from both
biomedical and psychosocial modalities (Fawcett, 2005). Further research on integrative,
biopsychosocial treatments will most likely allow for better understanding of the
mysterious phenomena of FMS. Psychoeducational group approaches that feature the use
of multidisciplinary treatment components may offer a way of improving the lives of
individuals diagnosed with FMS. Thus, the following hypotheses will be examined in this
study.
1. Following completion of the treatment group, FMS patients will show a

significant decrease in depression.
2. FMS patients who complete the treatment group will demonstrate significant

decreases in catastrophizing coping styles.
3. FMS patients who complete the treatment group will demonstrate a significant

increase in quality of life.
4. Patients in treatment group will report significantly lower levels of pain severity.

5. FMS patients who complete treatment group during the first 10 weeks of study
will be found to have maintained their progress with respect to depression,
catastrophizing, quality of life, and pain severity after a 10-week follow-up.
6. FMS patients who wait for treatment during the first 10 weeks of this study will
not evidence any change in depression, catastrophizing, quality of life, and pain
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severity until they participate in and complete treatment intervention during the
last 10 weeks.

Method

Participants
Twenty female FMS patients were recruited using referrals from Loma Linda
University (LLU) Family Medicine Residency Clinic, LLU Faculty Medical Offices, and
the LLU Psychological Services Clinic. To be included in the study, all participants
needed to have an FMS diagnosis given them by their physician. Even though men and
children make up a small portion of the FMS population, women are by far more likely
than men to experience FMS (Goldenberg, 1987). Thus, this study recruited only female
participants. Five participants dropped out of the study within the first two weeks. The
final number of participants was 15—7 in Group 1 and 8 in Group 2. These participants
were matched according to general impact of FMS symptoms (i.e., pain severity, muscle
stiffness, anxiety, depression) and then randomly assigned to either Group 1 or 2.

Instruments
Demographics. Simple demographic data such as age, socio-economic status
(SES), and ethnicity were obtained. These basic demographic variables were measured in
order to be used as possible covariates later in the statistical analysis. The variable of SES
was derived by using a modified version of the social status computation method first
developed by Hollingshead (as cited in Barratt, n.d.). The original four-factor SES
measure designed by Hollingshead has been extensively studied (Cirino et al., 2002).
Interrater reliability has been reported as being between .86 and .91; intermeasure
correlation between the Hollingshead measure and other assessments of SES have been
found between .81 and .88 (Cirino et al., 2002).
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Barratt (n.d.) modified the original Hollingshead measure by reducing it to a
three-factor scale aimed at the educational and occupational achievements of the
individual and both parents (spouse omitted). To produce an SES score, education and
occupation level for each patient and their parents were ranked on a Likert-type scale
from 1-7 for education and 1-9 for occupation (Appendix A). A patient’s educational
score was multiplied by five, and their occupational score was multiplied by three. This
same multiplication was carried out for the scores of each participant’s parents before all
scores being summed. Thus, each patient’s SES level represents a composite score out of
a possible score of 186.
Fibromyalgia. FMS pain was operationalized as the physical sensation of
discomfort as characterized by: (1) tender points on the body that are not caused by tissue
damage, and (2) unexplained generalized pain (Melzack & Katz, 2001). The Short-Form
McGill Pain Questionnaire (SF-MPQ) was used to measure this construct (Appendix B).
The SF-MPQ is a 15-item checklist containing lists of adjectives (i.e. throbbing, shooting,
etc.) that patients use to describe their pain experience (Melzack & Katz, 2001). The two
subscales of the SF-MPQ are sensory and affective (11 and 4 items, respectively), and it
was used in this study because of it ease of administration. The items are summed to
yield a Pain Rating Index (PRI) by taking into account the specific adjectives chosen as
well as the overall number of adjectives (Melzack & Katz, 2001). In order to measure
FMS patients’ pain experience, the SF-MPQ uses rating scale anchors of no pain (0),
mild pain (1), moderate pain (2), or severe pain (3). Higher scores denoted a more painful
experience for the participant.
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Love, Leboeuf and Crisp (as cited in Melzack & Katz, 2001) examined the testretest reliability of the MPQ on chronic back pain patients and found strong reliability
coefficients for the scale PRIs. A comparison of the SF-MPQ’s concurrent validity with
the full version of the MPQ shows a .70 correlation with the PRIs of both scales
(McDonald & Weiskopf, 2001). Also, the internal consistency of the SF-MPQ has been
reported as being between .72 and .85 (McDonald & Weiskopf, 2001). In this study, it
was found to have an alpha of .92. Another advantage of the SF-MPQ is that the
adjectives used are very easy for patients to understand as the adjectives tap specific
descriptors that patients commonly use to express their pain experience (Melzack & Katz,
2001). Thus, it appears that the use of the SF-MPQ in measuring FMS pain is supported.
Depression. Depression was measured using the Center for Epidemiologic Studies
Depression Scale (CES-D) and operationalized as affective feelings of moodiness,
helplessness, hopelessness, and negative self-worth (McDowell & Newell, 1996). The
CES-D (Appendix C) was put together using items from the Beck Depression Inventory
(BDI) and other well-established depression measures (McDowell & Newell, 1996). The
CES-D’s 20 items are scored on a Likert-type scale from 0 (rarely or none of the time) to
3 (most or all of the time). An example would be asking a participant to rate themselves
on how often during the past week they have “felt that people dislike [them]” (McDowell
& Newell, 1996).
The CES-D has been found to have internal consistencies of .85 in the general
population and .91 in clinical populations (McDowell & Newell, 1996). In this study, it
was found to have an alpha of .91. Split-half reliabilities have been reported between .76
and .85. Test-retest correlations, however, have been reported as often ranging between
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only .5 and .6. This may be due to the temporal nature of the questions in only asking for
responses in terms of the previous seven days (McDowell & Newell, 1996). Regarding
convergent validity, the CES-D has been found to correlate between .44 and .69 with the
Hamilton Rating Scale for Depression and .56 with clinical ratings (Radloff, as cited in
McDowell & Newell, 1996).
The content of the CES-D seems to have good face and content validity, mainly
because of its close ties with the BDI and the MMPI-2 (Minnesota Multiphasic
Personality Inventory—2nd Edition) (McDowell & Newell, 1996). For example, a
question regarding how often a participant felt depressed in the last week is very
straightforward to answer. The CES-D also includes four reverse-scored items (i.e. “I
enjoyed life”) to guard against response sets. Higher scores on the CES-D denote
increased depression, and a score of 16 (out of the total of 60 points) or above indicates
the cutoff point for clinical depression.
Catastrophizing. This study investigated the coping behavior of catastrophizing
using the Coping Strategies Questionnaire (CSQ). The version of the CSQ (Appendix D)
chosen for this study includes 23 coping statements that are anchored on a scale from 0
(never do) to 6 (always do). The CSQ has been supported as a valid measure for FMS
patients (Burckhardt & Henriksson, 2001). Its internal consistency tends to range
between .57 and .89 (Gil et. al., 1989; Keefe et. al., 1987; Spinhoven et. al., 1989), and it
was found to have an alpha of .89 in this study. This survey was devised to assess the
coping strategies of catastrophizing, diverting attention away from pain, reinterpreting
painful sensations, and relying on cognitive coping self-statements. An example of a
catatrophizing subscale item is “I feel I can’t stand it anymore.”

45
Quality of life. This construct was measured using the World Health Organization
Quality of Life Assessment—Abbreviated Version (WHOQOL-BREF). The WHOQOLBREF (Appendix E) was designed to assess subjective quality of life across four
domains: physical health, psychological well-being, social relationships, and environment
(Skevington et al., 2001). All 26 items are on a 5-point Likert-type scale. For example, a
question on this survey asks, “How healthy is your physical environment?” Internal
consistencies between .71 and .86 have been found for individual domain scores, and the
WHOQOL-BREF has also demonstrated acceptable discriminant validity between sick
and well populations (Skevington et al., 2001). In this study, the WHOQOL-BREF
demonstrated a high alpha of .93.

Procedure
Participants were screened and matched according to global impact of FMS
symptoms and then randomly divided into one of two groups. This measure assessed
patients’ subjective ratings of their pain, fatigue stiffness, anxiety, and depression on a 110 Likert-type scale. No more than a 1.1-point average difference of FMS impact
separated matched members. Group 1 received the treatment component for the first 10
weeks while Group 2 waited to receive the treatment intervention during the last 10
weeks. Before attending the treatment group or filling out any surveys, participants
signed an informed consent (Appendix F) and were given a flyer explaining the purpose
of the study and the inducement of a $50 gift certificate that would be given to them at
the completion of the study. At the beginning of the study, both groups completed pretest
questionnaires involving demographics, FMS pain, coping styles, depression, and quality
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of life. A posttest containing the same surveys was given at weeks 10, 11, and 20. Thus,
full assessments were completed during 4 of the 20 weeks of the study. For each of the
remaining 16 weeks, participants filled out abbreviated questionnaires on FMS pain
levels, coping styles and quality of life.
FMS pain was measured using the Short-Form McGill Pain Questionnaire.
Depression was measured via the Center for Epidemiologic Studies Depression Scale.
Catastrophizing was evaluated with the Coping Strategies Questionnaire. Quality of life
was measured using the World Health Organization Quality of Life Assessment—
Abbreviated Version. Participants completed the questionnaires weekly using one of
three methods: hard copy of the survey mailed to their residence, hard copy of the survey
completed at the treatment group, or online survey that was sent to their email address.
Hard copies of completed questionnaires were secured in a locked research lab.
The intervention tested in this study consisted of a psychoeducational group that
met once a week. The first 45 minutes of group sessions featured a group process led by a
trained facilitator. This clinician led out group discussions on clinically relevant topics in
order to bolster social support, process presented information and homework assignments
given during the previous week, and assist in planning of self-care. The remaining 45
minutes of each session featured an outside expert who disseminated educational material
to the participants across a broad range of subjects (Appendix F)—FMS facts and myths,
physical therapy, occupational therapy, cognitive-behavioral therapy, relaxation
techniques, dual diagnosis, family therapy, sleep hygiene, and dealing with trauma. A
licensed professional expert in their respective field gave each presentation. For example,
a psychiatrist presented information regarding dual diagnosis issues. Group members
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were given worksheets for each specific topic so that they could tailor the salient
educational material to their specific needs. Thus, each treatment session lasted 90
minutes. Wait-listed participants were given pretest and posttest assessments so that
comparisons could be made between groups.

Results

Data Screening
The sample consisted of 15 female participants. The average age was 54 years,
and the sample was predominantly Caucasian (Table 1). All study variables except the
Reinterpreting Pain Sensations subscale of the CSQ were found to approximate a normal
distribution and did not show evidence of skewness (Table 2) or univariate outliers. A
Mahalonobis distance was calculated to check for multivariate outliers. One such outlier
was discovered but left in this study because it represented a posttest score for a member
of Group 2. Given the exploratory nature of this study and the fact that removal of this
case would have resulted in even smaller group membership, data analyses were
conducted with this case included. Parametric assumptions of homogeneity of variance
and homoscedasticity were met for all variables. Of the demographic variables, ethnicity
and SES were found to significantly correlate with the study variable of pain (Table 3).
However, given that there were no differences between groups for either variable,
variance from this correlation was not removed during statistical analysis.
Paired-sample Mests for pretest and posttest scores were conducted in order to
check for possible relationships between study variables. For Group 1, scores from weeks
1 and 11 were used for pretests and posttests, respectively. This was done in order to
capture the entire effect of the treatment through the last week of the treatment period.
Since these patients participated in group activities during week 10, they were not able to
report the effect of those activities until week 11. Thus, Week 11 was chosen as the
posttest for Group 1. For group 2, Weeks 10 and 20 were used for pretests and posttests,
respectively.
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Due to the exploratory nature of this study, acceptable p-value limits were set at
the .10 level with two-tailed tests. This is not an uncommon practice in exploratory
studies, with reported p values being relaxed to levels as high as .25 (Levitt et al., 2004;
Hladiuk, Huchcroft, Temple, & Schnurr, 1992).

Table 1
Sample demographics
Age
Ethnicity
Caucasian
Black

Mean
54

SD
11.4

Education
Less Than 7th Grade
Partial High School
High School Graduate
Partial College
College Grad
Partial Grad School
Graduate Degree
Occupation
Farm Laborer/Day Laborer
Unskilled Worker/Service Worker
Machine Operator/Semiskilled Worker
Skilled Manual Worker/Law Enforcement/Military
Clerical/Sales/Small Farm Owner/Teacher, etc.
Techni ci an/S emipro fessional/Offi ce Manager
Small Business/Farm Owner/Teacher
Midlevel Manager/Professional
Senior Manager/Professional

Frequency
14
1

0
0

1
2

5
5
2

0
0
0
0
3
7

1
4
0
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Table 2
Means, standard deviations, and skewness statistics
Variables

Scale

M

SD

Skew

Quality of Life

1-5

2.92

13.79

.283

Pain

0-3

1.42

10.49

.091

Depression

0-3

1.14

10.97

.120

Catastrophizing

0-6

1.76

9.39

-.689

Diverting Attention

0-6

2.45

7.84

.070

Reinterpreting Pain Sensations

0-6

.66

6.04

2.08

Cognitive Coping

0-5

2.52

6.32

.559

Coping
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Table 3
Correlations between demographic and study variables
Variable

1

2

3

4

6

5

7

1. Age
-.356

2. SES
3. Ethnicity

125

-.369

4. Quality of life .132

.329

.127

5. Pain

.192

-.4161

.495

-.597

6. Depression

-.044

-.354

-.240

-.761** .793**

7. Catastrophizing-.267

-.266

.322

-.622

.694

sksk

.566

Above values reflect two-tailed tests of significance.
Ethnicity was “dummycoded” with 1 = White/Caucasian and 2 = NonWhite/Caucasian fp< A *p< .05 **p < .01

Data Analysis
Hypothesis #7. Paired-sample t tests were used to test the first study hypothesis
that there would be a significant decrease in depression following completion of the
treatment group. At the beginning of the study, there were no significant between-group
depression differences {t = -.40, p = .70) (see Table 4 and Figure 5). Significant
depression reductions were evident for Group 2 during their treatment phase; this was not
found in Group 1 (Table 6). It is important to note that only 5 patients in Group 1 were
included in this analysis because the remaining two members joined the group late and
did not complete CES-D pretests. Cohen’s d effect sizes for each group were .98 and
1.41, respectively, indicating a large effect.
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In order to control for disparities in pretest depression, independent Mests
measured differences between change scores over both halves of the study. As depicted
in Table 5 and Figure 5, Group 2 demonstrated a significantly greater rate of decrease in
depression levels than Group 1 over the last half of the study (Cohen’s d = .72)

Table 4
Independent-sample t-test measuring between-group differences in study variables
at start (Time 1), middle (Time 2), and end ofstudy (Time 3).
Variable
Depression

Group
1

Time
1

N
5
8

Mean Difference t
-.40
-2.78

Cohen’s d
-.24

2

7

.09

.02

.01

3

7

7.54

1.16

.64

1.96

.40

.22

-4.70

-.92

51

17

-.09

-5.96

-.96

-.53

-3.63

53

-.29

-17.84

-2.59*

-1.44

3.13

.85

.51

-5.45

-.91

-.55

1.23

.17

.10

2

1

8

2

1

8

2

Catastrophizing 1

1

1

2
3

1

1

7

2

7

3

7

8

2

1
2

Pain

1

1

2

1

2

2

1
2

82

8

2

1

7

8

2

Quality of life

7

8

2

1

7

8

2

3

8
5
8
5
8
5
8

4-

s|c

**

Above values reflect two-tailed tests of significance. p< A /? < .05 /? < .01
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Table 5
Independent-sample X-test measuring rate of change differences in between-group
outcome scores at middle (Time 2) and end ofstudy (Time 3).
Variable
Depression

Group
1

N
5
8

Mean Difference t
-2.05
-.36
7.45

l.SO1

.72

2

7
8
7

-6.66

-1.52t

-.84

3

7

3.88

1.63't

.90

1.71

.38

.21

-14.21

-3.53

-5.58

-1.59t

-.96

-6.68

1.01

.61

Time
2

2

1

3

2

Catastrophizing 1

8

2

1

8

2

Quality of life

1

2

7

8

2

1

3

2

Pain

Cohen’s d
-.22

1

2

2

1

3

2

7

8
5
8
5
8

5}c

sk 5k

-1.96

$|£ *{;

Above values reflect two-tailed tests of significance. p< A p< .05 p < .01
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Figure 5. Between-group differences for depression levels and rate of
depression changes. Above values reflect two-tailed tests of significance, p <

.1 V<.05 *V<.01
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Table 6
Paired-sample t-test for treatment group as predictor of
depression decrease. (Hypothesis #1) (Group 1 N = 5,
Group 2 = 8)
Group

Mean Difference

t

1

-4.80

.73

2

-6.88

Above values reflect two-tailed tests of significance.
p<A p<.05 p < .01
4.

**

Hypothesis #2. The second hypothesis was that FMS patients who completed the
treatment group would demonstrate significant decreases in catastrophizing coping styles.
There were no significant differences in catastrophizing prior to the beginning of
treatment (t = .40, p = .70) (Table 4, Figure 6). Paired sample Mests were used once
again, and the results indicated that catastrophizing decreased significantly in Group 1
but not Group 2 (Table 7). Cohen’s d was 1.07 and .15, indicating a large effect for
Group 1 only. When comparing change scores to control for disparities in starting
catastrophizing scores, both groups showed significant improvements across time
compared to each other’s change scores (Table 5). Cohen’s d effect sizes were moderateto-large for both groups (-.84 and .90, respectively).
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Figure 6. Differences between group catastrophizing levels and catastrophizing
change scores. Above values reflect two-tailed tests of significance. < .1 p<
.05 p < .01
sksk

Table 7
Paired-Sample t-test for Treatment group as predictor of
decrease in catastrophizing coping style. (Hypothesis #2)
(Group 1 N = 7, Group 2 = 8)
Group

Mean Difference

t

1

-8.29

2.03

2

-1.88

.966

9|e

Above values reflect two-tailed tests of significance.
p<A p < .05 p<.0\
4-

sk

sfcsic

_ _

Hypothesis #3. This study’s third hypothesis was that FMS patients who
completed the treatment group would demonstrate a significant increase in quality of life.
No significant difference was found between groups for quality of life at the beginning of
this study (t = -.96,p = .36) (Table 4, Figure 7). When comparing within-group pre-post
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differences, quality of life did not increase for Group 1 but did significantly increase for
Group 2 (Table 8). Cohen’s d was -.13 and -.56, indicating a medium effect for Group 2
only. In regards to differences in change scores between groups over time, Group 2’s
increase in quality of life was significantly greater than any changes in Group 1 ’s quality
of life over the last half of the study (Table 5; Cohen’s d = -1.96).

120
100
80

**

f§:

♦

*

O 60

a

Group 1
Group 2

40
20
0
1

2

3

Study Phase

Figure 7. Differences between group quality of life levels and quality of life
change scores. Above values reflect two-tailed tests of significance. ^p< A p <
.05 pc .01
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Table 8
Paired-Sample t-testfor treatment group as predictor of increase in quality of life.
(Hypothesis #3) (Group 1 N = 7, Group 2 = 8)
Group

Mean Difference

t

1

-1.71

-.501

2

-8.5

-2.62*

Above values reflect two-tailed tests of significance.
p<.\ p<.os p<m
4.

*

**

Hypothesis #4. Even though ethnicity and SES were found to correlate with pain,
their variance was not removed because neither variable demonstrated differences
between groups (Ethnicity: t = -.88,= .40; SES: t = -.26, p = .80). There were no
significant differences between groups in terms of pretest pain (t = .85,/? = .41) (Table 4,
Figure 8). Following treatment, paired Mests found that only Group 1 members
experienced a statistically significant decrease in pain (Table 9). Cohen’s d was .91,
indicating a large effect. This finding was also supported using an independent-sample ttest to measure difference in change scores over both halves of the study. As shown in
Table 5, Group 1 ’s improvement in pain levels over the first half of the study was
significantly greater than any improvements in Group 2 pain (Cohen’s d = -.96).
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Figure 8. Differences between group pain levels and pain change scores.
Above values reflect two-tailed tests of significance. p< A *p< .05 **p <
.01

Table 9
Paired-Sample t-test for Treatment group as predictor of
pain decrease. (Hypothesis #4) (Group 1 N = 5, Group 2
= 8)
Group

Mean Difference

t

1

7.2

2.22*

2

5.13

1.06

Above values reflect two-tailed tests of significance.
4*
**
_ ^
p<.\ /?<.05 p<.0\

Hypothesis #5. This study’s fifth hypothesis was that FMS patients who
completed the treatment group during first 10 weeks of study (Group 1) would be found
to maintain their progress with respect to depression, catastrophizing, quality of life, and
pain severity after a 10-week follow-up. As shown in Table 10, this hypothesis was
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supported in terms of depression and pain outcomes. However, catastrophizing was
significantly increased and quality of life was significantly decreased at follow-up.

Table 10
Paired-Sample t-test for Group 1 measuring change at 10-week follow-up.
Mean Difference

Variable

N

Depression

7

57

19

Quality of life

7

5.71

2.64

Pain

5

-1.8

72

Catastrophizing

7

-2.00

-i.es1
j.

jjc

t

^

Above values reflect two-tailed tests of significance. p< A p< .05 p < .01

Hypothesis #6. The last hypothesis put forth in this study posited that FMS
patients who waited for treatment during the first 10 weeks of this study would not
evidence any changes in depression, catastrophizing, quality of life, and pain severity
until they participated in and completed treatment during the last 10 weeks of the study
(Group 2). This hypothesis was supported as Group 2 showed no significant changes
across depression, quality of life, pain, or catastrophizing outcomes, during the first 10
weeks of the study (Table 11).
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Table 11
Paired-Sample t-test for Group 2 measuring baseline changes
before start of 10-week treatment. (N— 8)
Variable

Mean Difference

t

Depression

2.75

1.31

Quality of life

.63

.22

Pain

1.38

.69

Catastrophizing

1.63

.79

Above values reflect two-tailed tests of significance.
f<A p < .05 p < .01
J-

sjc

sic*

Further analyses. Additional group analyses were conducted in order to measure
the coping strategies of diverting attention and cognitive coping. Table 12 illustrates that
only Group 2 demonstrated statistically significant decreases in diverting attention and
increases in cognitive coping.

61
Table 12
Paired-Sample t-test for Treatment group as predictor of decrease in diverting
attention and increase in cognitive coping. (Group 1 N = 7, Group 2 = 8)
Mean Difference

Variable

Group

Diverting Attention

1

14

Diverting Attention

2

-3.50

-1.62*

Cognitive Coping

1

2.70

1.41

Cognitive Coping

2

-2.88

-3.08*

t

-.09

•j-

*

jfc jjc

Above values reflect two-tailed tests of significance. p< A p < .05 p< .01

Other analyses checked whether groups displayed any differences in terms of
participation. This was measured by examining group differences across reported number
of weekly exercise routines and completion of group handouts that were distributed at the
close of every treatment group meeting (i.e. homework). As can be seen in Table 13,
there was no difference between groups in terms of reported exercise {t = -1.32,/? = .21).
Regarding homework, however, Group 2 reported completing their assignments 61% of
the time, whereas Group 1 only reported a completion percentage of 32%. This represents
a statistically significant difference between groups (x2= 5.87, p = .02).
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Table 13
Independent-Sample t-test for differences between
group exercise levels during treatment. (Group 1 N
= 7 Group 2 = 8)
Group

Mean

1

3.07

2

3.54

t

-1.32

Above values reflect two-tailed tests of significance.
fp<.\ p < .05 p < .01

Post hoc exploration. In order to investigate the possible presence of treatment
effects across individual group member scores, case analysis was employed. This TV of 1
statistical technique involves examining the means of scores produced during a treatment
phase versus the mean of scores generated during a baseline phase (Gorsuch, 1983).
Traditionally, various time series designs have been suggested as more powerful than
single-A designs, but case analysis has been found to be as effective and precise as largerA analyses (Gorsuch, 1991).
Case analysis calls for data from each time point (in this case, weekly
measurements) to be entered as separate cases in order to produce a dichotomous
treatment status variable (baseline vs. treatment). A Mest is then computed between this
treatment variable and the selected criterion variable (depression, quality of life, etc.)
(Gorsuch, 1983). If treatment status significantly predicts positive outcomes, inferences
can be made about the effectiveness of the treatment. Since this type of analysis is
primarily suited for data with a true baseline prior to an intervention, individuals in
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Group 2 were selected. Because Gorsuch cautions that autocorrelation of error scores can
result in highly unreliable findings, this study screened for and found no evidence of
residual score correlation between wait list and treatment phase data.
Six out of the eight members of Group 2 were found to show statistically
significant improvements in at least one of the outcome variables of quality of life, pain,
catastrophizing, and cognitive coping. Two members indicated improvements in two of
these variables. For the outcome variable of quality of life, Group 2 members A, B, and F
demonstrated significant improvements (Table 14, Figure 9). Members B, D, and F
featured significant decreases in catastrophizing following treatment (Table 15, Figure
10). One Group 2 member (C) displayed a significant reduction in pain levels (Table 16,
Figure 11), and member E exhibited a significant increase in cognitive coping (Table 17,
Figure 12).

Table 14
Case analysis i-test measuring improvement in
quality of life as predicted by treatment status.
Group Member

r

A

.36

B

.52

2.58*

F

.56

2.90

t

Above values reflect two-tailed tests of significance.
p < A p < .05 p < .01
JL

*

**
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Figure 9. Sequence plot of Group 2 members who showed improvement in
quality of life over time. Group 2 members began treatment group on week
11.

Table 15
Case analysis t-test measuring decrease in
catastrophizing coping style as predicted by
treatment status.
Group Member

r

t

B

.50

-2.42

D

.53

-2.64

F

.53

-2.57

9j«

*
*

Above values reflect two-tailed tests of significance.
p<.\ p < .05 p < .01
J-

s|<

Sjcjjc
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Figure 10. Sequence plot of Group 2 members who showed improvement in
catastrophizing over time. Group 2 members began treatment group on week
11.

Table 16
Case analysis t-test measuring pain levels as
predicted by treatment status.
Group Member

r

C

.36

t

Above
values
reflect
two-tailed tests of significance.
4*
**
p < A p < .05 p < .01
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Figure 11. Sequence plot for Group 2 member who showed improvement in
pain level over time. Group 2 members began treatment group on week 11.

Table 17
Case analysis t-test measuring cognitive coping
as predicted by treatment status.
Group Member

r

t

E

.31

l.40f

Above
values
reflect
two-tailed tests of significance.
x
*
**
p<A p<.05 p < .01
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Figure 12. Sequence plot for Group 2 member who showed cognitive coping
improvement over time. Group 2 members began treatment group on week 11.

A qualitative examination of Group 2 members reveals a difference that may have
contributed to varying degrees of treatment effectiveness. Group 2 members who showed
statistically significant improvement across study variables (hereafter, responders) all
reported no medication changes during the treatment phase of the study. Only one
responder reported medication changes during any part of the study, and the medication
was an over-the-counter glucosamine supplement added near the end of the wait list
phase. Both individuals who did not display significant improvements (hereafter, non
responders) reported changes in their pain medications during the treatment phase. These
changes were an increased dose of duloxetine and the commencement of pregabalin use.
Thus, it may be that the ability of non-responders to benefit from the treatment
intervention was somewhat stifled by changes in their medication regimen.
Another case analysis was computed for members of Group 1. Even though their
inclusion in the first treatment phase of the study meant that they did not generate a true

68
baseline, each Group 1 member was matched with a Group 2 counterpart that served as a
baseline based on global FMS impact. Since there was one more member in Group 2 than
in Group 1, the Group 2 member with the most discrepant FMS impact score was
dropped from this analysis and not used as a match for any Group 1 member.
For this case analysis, difference scores to correct for time were computed for
Group 1 members during the first half of the study. A Mest was calculated between these
values and difference scores generated by their Group 2 counterparts during the first half
of the study. No Group 1 members were found to demonstrate statistically significant
improvements in quality of life, pain, catastrophizing, or cognitive coping above and
beyond the baseline provided by their matched Group 2 counterparts.

Discussion

Inconsistent support was found in relation to this study’s six hypotheses.
Hypothesis 1 posited that members of both groups would experience significantly lower
levels of depression following exposure to the treatment phase of the study. Statistical
analysis rendered partial support for this hypothesis as only Group 2 depression
significantly decreased following treatment. This difference was found for Group 2 when
measuring within as well as between group changes over the treatment period. A possible
reason for why both groups did not experience depression decreases may be that Group 2
members had greater expectations regarding the treatment’s efficacy as a result of having
to wait until the second half of the study to receive treatment. Alternatively, Group 1 was
found to complete study-related homework significantly less often than their Group 2
counterparts. Though no differences were found between group exercise levels during
treatment, Group 1 was much less likely to complete study related materials. Therefore, it
is unknown whether this inconsistent form of participation could also have typified group
members’ exercise involvement. Nevertheless, Group 1 may have experienced no
reduction in depression levels due to their restricted participation in treatment.
Since neither group approached a high level of treatment adherence (i.e.
homework completion) throughout the study, questions remain concerning what may
have prohibited participants from fully adhering to the intervention. Research applying
the transtheoretical model (TM) with chronic pain populations has struggled to identify
the exact components that keenly predict a participant’s ability to effectively engage in
the self-management strategies put forth is psychoeducational interventions (Carr,
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Moffett, Sharp, & Haines, 2006). Currently, there is some debate in the literature
whether questionnaires measuring TM stages of change (Precontemplation,
contemplation, action, maintenance) can identify pre-study profiles of patients who are
unlikely to complete self-management interventions (Carr et ah, 2006; Biller, Amstein,
Caudill, Federman, & Guberman, 2000; Kerns & Rosenberg, 2000; Jensen, Neilson,
Romano, Hill, & Turner, 2000).
The second hypothesis was that catastrophizing coping strategies would diminish
as a function of treatment. Curiously, only Group 1 showed significant reductions in
catastrophizing. Though Group 2 displayed a significant between-group reduction in
catastrophizing when taking change scores into account, this supposed improvement
appears to be more attributable to Group 1 ’s inability to maintain previous
catastrophizing improvements. Thus, change scores generated during the second half of
the study were more influenced by Group 1 ’s increase in catastrophizing rather than
tangible decreases in Group 2 catastrophizing.
There does not appear to be a clear reason why Group 2 did not significantly
improve regarding catastrophizing. One possible cause could be a lack of sensitivity by
this study’s coping measure (CSQ). Another alternative explanation could be that Group
2 experienced cognitive growth as evidenced by their depression decrease that did not
generalize to alleviate the strong emotional reactions often associated with FMS. Group
1, however, may have benefited enough from social support aspects of the treatment to
produce a quieting of their emotional response without integrating workable treatment
strategies to combat depressed cognitions.
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A closer inspection of Group 2’s catastrophizing scores through the use of
individual case analysis did find evidence, however, of a treatment effect in three Group
2 members. Thus, it is likely that the group-level findings of nonsignificant
catastrophizing levels were not emblematic of every participant in Group 2. This is not
surprising given this study’s lack of power.
Additional analyses conducted on the CSQ subscales of Diverting Attention and
Cognitive Coping revealed a significant increase on both variables for Group 2 during
their treatment phase. Significant research has been done regarding the higher tendency
of depressed individuals to selectively attend to negative aspects of their emotional
experience (Koster, Raedt, Goeleven, Franck, & Crombez, 2005; Beevers & Carver,
2003). Individuals in Group 2 appeared to selectively attend less to their pain experience
and focus more on cognitively-based coping strategies during treatment. This may
partially explain the reduction in depression displayed by Group 2 and provide evidence
for the process by which the intervention was effective for some areas of FMS symptom
management.
The third hypothesis that treatment group members would demonstrate significant
increases in quality of life also received partial support. Group 2 members showed a large
effect regarding significant quality of life improvement relative to their baseline and
when matched against Group 1 change scores. Despite overall quality of life
improvement on the group level, case analysis of Group 2’s scores shows that there was a
high degree of variability for quality of life scores across the entire study, even for
specific group members who indicated a strong treatment effect. This is a particularly
common finding according to Ayan and colleagues (2007), and it represents a
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methodological quandary with FMS patients because widely disparate modes of
responding often obscure the meaning of their self-reports. Measurement weaknesses in
this study may also have contributed to inconsistency across responses. Since FMS
patients in both groups were allowed to complete surveys either online, by regular mail,
or at the beginning of the group meetings, environmental cues may have caused
differences across responses. For example, individuals who usually filled out mail
surveys may have produced depressed quality of life scores because they did so in an
environment where they are conditioned to feel helpless.
Partial support was generated for this study’s fourth hypothesis—that treatment
would produce significant reduction in pain levels. Group 1 experienced a significant
pain decrease relative to pre-test scores and when compared to concurrent difference
scores between groups. A medium effect was generated for this difference. Group 2 did
not show evidence of significant group-level pain reduction, and only one member of
Group 2 was found to have experienced a significant decrease in pain across the length of
this study.
Group 1 ’s large effect size concerning within-group pain level decrease is rather
baffling considering that these group members showed no significant changes in quality
of life or depression during the treatment phase. Recent research on the functioning of
pain, depression, and anxiety in FMS populations does suggest, however, that pain
reduction does not necessarily entail concomitant changes in affective functioning
(Arnold, Crofford, Martin, Young, & Sharma, 2007). Therefore, the reduction in pain
experienced by Group 1 possibly had less to do with participation in and benefit from the
treatment phase of the study and perhaps was influenced by an extraneous third variable
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(i.e. concurrent medication use). If Group 1 experienced a positive pain-related effect
primarily from their medication use, they would probably be less prone to adaptively
integrate the treatment materials in a way that could affect any associated anxiety or
depression (Arnold, Crofford, et ah, 2007).
Another possible reason for the discrepancy between group pain levels was that
the treatment was not focused enough to produce the desired effect during the Group 2
treatment phase. While both groups reported varying levels of participation with respect
to completion of study material, this could still be objectively measured by examining
returned homework handouts. However, it is impossible to ascertain the consistency of
each group’s use of regular exercise since these activities were not directly supervised or
objectively measured. Previous studies featuring psychoeducational interventions have
also produced small effect sizes in terms of actual pain reduction following subjectively
reported exercise (Havermark & Languis-Eklof, 2006). It seems apparent that future
studies measuring psychoeducational group designs would benefit from the inclusion of
supervised aerobic exercise in order to correct for self-report inaccuracies.
This study’s fifth hypothesis was that changes evident following treatment would
be maintained when measured at a 10-week follow-up. Only Group 1 scores qualified for
this hypothesis because this group received treatment during the first half of the study.
This hypothesis was supported only for the outcome variable of pain, as Group 1 was
found to have significantly reduced pain after treatment and no significant differences in
pain at follow-up. However, Group 1 demonstrated significantly lower quality of life at
the conclusion of the study after having had no change in quality of life during the
treatment phase. Interestingly, Group 1 also produced significant increases in
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catastrophizing at follow-up, though these group members had initially generated
statistically significant decreases in catastrophizing during the first half of the study. No
significant changes were found for depression at any point in the study.
It is unclear what mechanism may have produced such quick, contrasting
outcomes in Group 1 members. Once again, it is probable that high variability across item
responses may be partly responsible for these results. Another possibility is that
environmental cues and social support variables may have affected the way that Group 1
members responded to treatment. Constructs such as quality of life and catastrophizing
are thought to be intimately connected with socially-derived reinforcement (Bergman,
2005). The group format of this study’s intervention naturally features a social
component that was not directly measured. However, it is entirely possible that FMS
patients benefited directly from the social support of the groups and consequently
experienced less quality of life and more opportunity for unchecked catastrophizing once
they completed treatment and returned to their normal environments. Furthermore, some
of the treatment effects produced by FMS patients in this study may have potentially been
due to the Hawthorne Effect—the tendency to behave differently simply because a
participant knows they are receiving a treatment or being studied (Lemstra & Olszynski,
2005).
Though difficult to achieve in studies that feature psychoeducational
interventions, future studies may be wise to incorporate blinding procedures whereby
patients are divided between three groups—psychoeducational treatment, control, and
social support groups. The inclusion of a third group would not necessarily blind group
members from knowing they are receiving treatment, but measuring the effect of social
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support aside from psychoeducational materials may separate out some of the overlap
that could be evident in this study.
The sixth and final study hypothesis was that individuals in Group 2 would not
show evidence of improvement in outcome variables prior to receiving treatment during
the last half of the study. This hypothesis was supported, as Group 2 evidenced no
significant baseline changes of any kind with regard to depression, catastrophizing,
quality of life, or pain.

Limitations
This research sought to explore a psychoeducational treatment approach for
FMS symptom management. While this intervention produced some measurable
improvements in outcome variables over time, several key weaknesses are apparent.
Though this study featured a sample largely representative of the general FMS
population, an extremely small sample of participants was actually used. Also, a quarter
of the participants who initially agreed to engage in this study dropped out shortly after
the start of the study.
Given the small sample and inherent lack of power generated by this size, this
exploratory study relaxed the accepted level of statistical significance from .05 to .10
(two-tailed). With so few participants, the possibility for family-wise alpha inflation
presents a strong threat to the validity of these results. Additionally, less stringent
screening measures were taken in order to preserve the sample size of the groups (i.e.
inclusion of one multivariate outlier). Hence, interpretations based on this study’s
findings must be done so conservatively and with the understanding that the results only
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represent cautiously supported hypotheses regarding the intervention and its effect on
outcome variables.
A methodological weakness of this study was that group members were afforded
multiple options for survey completion—paper/pencil surveys via postal service, online
surveys, and paper/pencil surveys at group sessions. This provided added noise to the
consistency of item responses due to a couple different reasons. First, individuals filled
out surveys in different environments (at home vs. group setting). These environmental
cues may have affected how group members reported their in-the-moment response to
treatment. Second, while all group participants completed weekly surveys, group
members often had to be reminded to complete surveys in a timely fashion. Thus, on
various occasions, group members would not complete their surveys at the exact time
every week. These inconsistencies may have produced additional variability across
individual weekly outcome scores.
The results of this study are further tempered by the fact that only one group
produced a true baseline (Group 2) or follow-up assessment (Group 1). With modest
baseline data available and by only being able to check follow-up results for half the
sample, this study’s capacity to measure true pre-post change was limited. Furthermore,
in all phases of this study (baseline, treatment, follow-up), both groups demonstrated a
high degree of variability in outcomes scores. Therefore, only cautious generalizations
regarding the long-term benefits of this study’s intervention are suggested.
Another difficulty encountered during this study was the general issue of
treatment adherence. Group 2, which showed the most improvement during the study,
only completed group homework assignments 61 % of the time, and Group 1 did so
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roughly half as often as Group 2. It seems possible that the meager findings generated by
this study may have been depressed by low adherence from the group participants.
Research regarding trends in treatment adherence suggests that a couple factors
likely affect whether or not FMS patients follow through on the directives given them by
health care providers—^treatment characteristics and participant variables (Huyser,
Buckelew, Hewett, & Johnson, 1997). Treatment characteristics often involve the
tendency of participants to adhere less when they are asked to perform a complicated
procedure as part of treatment. It is possible that the participants of this study found the
homework assignments and/or exercises too difficult to complete, thus hindering their
ability to fully profit from their group involvement.
Participant variables that affect treatment adherence involved issues such as
expectations, depression, and self-esteem. Since this study found that group members’
average depression scores were in the clinically significant range, it could be that this
study’s participants were somewhat limited at the start of this study in terms of how
capable they were in engaging with the groups. However, Huyser et al. (1997) found that
depression alone was not a significant predictor of poor treatment adherence. Rather,
depression likely predicts treatment adherence when combined with other variables such
as poor outcome expectancies and negative self-esteem (Huyser at ah, 1997; Ogden &
Sidhu, 2006). Nevertheless, it seems plausible that unmeasured, extraneous variables
such as poor treatment expectations and negative self-esteem may have compromised
participants’ ability to adhere to and benefit from treatment.
Another participant factor that may have contributed to low adherence is that at
least some of this study’s participants could possibly be classified as being in a
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precontemplation stage of change. Precontemplation is the first stage in TM and it is
typified by an ambivalent attitude towards change where a person has given little thought
or intention to modifying a current behavior (Kerns & Rosenberg, 2000). Carr et al.
(2006) pointed out that participants high on precontemplation prior to a multidisciplinary
treatment were less likely to engage in study-related activities or find some level of
acceptance in regards to their pain experience. Therefore, participants’ attitudes regarding
their ability to employ the self-management strategies put forth as part of this
psychoeducational intervention may have contributed to their poor adherence to studyrelated materials.

Conclusions
The intervention implemented in this study featured multidisciplinary
psychoeducational group presentations with two different groups of female FMS patients.
Group 1 significantly improved in tenns of pain and catastrophizing after treatment but
only maintained pain-related gain at follow-up. Group 2’s depression decreased and
quality of life increased following treatment. Qualitative differences were found between
groups in that Group 2 showed more overall participation than Group 1 during treatment.
This study suggests that psychoeducation coupled with physical exercise seems capable
of providing FMS patients with some level of symptom relief.
Future studies measuring the effect of psychoeducational treatment with FMS
patients would most likely benefit from the inclusion of larger sample sizes, a supervised
exercise component, and one uniform method of survey completion. More stringent
participant screening may be helpful in order to gauge the effect of extraneous variables
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such as treatment expectations, self-esteem, readiness/intention for change, and social
support on physical and psychosocially-related FMS symptoms. Also, future studies may
be advised to consider a longer treatment period while incorporating fewer distinct
psychoeducational topics in order to focus the treatment and allow greater insights in the
long-term effects of the intervention on FMS symptom management.
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A Modified Hollingshead 3-Factor Index of Social Status
Will Barratt, Ph.D.

Circle the appropriate number for your Mother’s, your Father’s, and your level of school
completed and occupation. If you grew up in a single parent home, circle only the score
from your one parent. If you are a full time student circle only the scores for your parents.

Mother

Level of School Completed

Father

You

Less than 7th grade
Junior high (9th grade)
Partial high school (10th or 11th)
High school graduate
Partial college (at least one year)
College degree
Graduate degree

Circle the appropriate number for your Mother’s, your Father’s , and your occupation. If
you grew up in a single parent home, use only the score from your parent. If you are still
a full-time student only circle the scores for your parents. If you are retired use your most
recent occupation.
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Occupation
Farm laborer, day laborer
Unskilled worker, service worker
Machine Operator/Semiskilled Worker
Skilled Manual Worker/Law Enforcement/Military
Clerical/Sales/Small Farm Owner/Teacher, etc.
Technician/Semiprofessional/Office Manager
Small Business/Farm Owner/Teacher
Midlevel Manager/Professional
Senior Manager/Professional

Mother

Father

You

SF-MPQ
Ronald Melzack

ID#:
Please rate the degree to which the following adjectives describe your
Fibromyalgia pain.
None

Mild

Moderate

Severe

Throbbing

0)

1)

2)

3)

Shooting

0)

1)

2)

3)

Stabbing

0)

1)

2)

3)

Sharp

0)

1)

2)

3)

Cramping

0)

1)

2)

3)

Gnawing

0)

1)

2)

3)

Hot-Burning

0)

1)

2)

3)

Aching

0)

1)

2)

3)

Heavy

0)

1)

2)

3)

Tender

0)

1)

2)

3)

Splitting

0)

1)

2)

3)

Tiring-Exhausting

0)

1)

2)

3)

Sickening

0)

1)

2)

3)

Fearful

0)

1)

2)

3)

Punishing-Cruel

0)

1)

2)

3)
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CES-D

Instructions for questions: Below is a list of the ways you might have felt or
behaved. Please tell us how often you felt this way during the past week.
Occasionally

During the past week:

Rarely or

Some or a

or a moderate Most all

none of

little of

amount of the of the

the time

the time

time

time

(3-4 days)

(5-7 days)

(less than 1 day) (1-2 days)

1. I was bothered by things

0

1

2

3

0

1

2

3

0

1

2

3

0

1

2

3

0

1

2

3

0

1

2

3

that usually don’t bother me
2. I did not feel like eating; my
appetite was poor
3. I felt that I could not shake
off the blues even with the
help from my family and

friends
4. I felt that I was just as
good as other people
5. I had trouble keeping my
mind on what I was doing
6. I felt depressed

96
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7. I felt that everything I

0

1

2

3

0

1

2

3

0

1

2

3

10.1 felt fearful

0

1

2

3

11. My sleep was restless

0

1

2

3

12.1 was happy

0

1

2

3

13.1 talked less than usual

0

1

2

3

14.1 felt lonely

0

1

2

3

15. People were unfriendly

0

1

2

3

16.1 enjoyed life

0

1

2

3

17.1 had crying spells

0

1

2

3

18.1 felt sad

0

1

2

3

19.1 felt that people dislike

0

1

2

3

0

1

2

3

did was an effort
8. I felt hopeful about the
future
9. I thought my life had
been a failure

me
20.1 could not get “going”

CSQ

Name:
Instructions: Individuals who experience pain have developed a number of
ways to cope, or deal with, their pain. These include saying things to themselves
when they experience pain, or engaging in different activities. Below is a list of
things that people have reported doing when they feel pain. For each activity,
please indicate, using the scale below, how much you engage in that activity
when you feel pain, where a 0 indicates you never do that when you are
experiencing pain, a 3 indicates you sometimes do that when you are
experiencing pain, and a 6 indicates you always do it when you are
experiencing pain. Remember, you can use any point along the scale.

0

1

Never
do

2

3

4

Sometimes
do that

5

6
Always
do that

When I feel pain...
1. I try to feel distant from the pain, almost as

0 1 2 3 4 5 6

if the pain was in somebody else’s body.
2. I try to think of something pleasant.

0 1 2 3 4 5 6

3. I don’t think of it as pain but rather a dull

0 1 2 3 4 5 6

or warm feeling.
4. It is terrible, and I feel it is never going to get any better.

0 1 2 3 4 5 6

5.

0 1 2 3 4 5 6

It is awful, and I feel it overwhelms me.
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1

0

2

Never
do

3

4

5

Sometimes
do that

6. I feel my life isn’t worth living.

6
Always
do that
0 1 2 3 4 5 6

7. I try not to think of it as my body, but rather
as something separate from me.
8. I tell myself I can’t let the pain stand in the way of

0 1 2 3 4 5 6
0 1 2 3 4 5 6

what I have to do.
9. No matter how bad it gets, I know I can handle it.

0 1 2 3 4 5 6

10.1 pretend it’s not there.

0 1 2 3 4 5 6

11.1 worry all the time about whether it will end.

0 1 2 3 4 5 6

12.1 replay in my mind pleasant experiences in the past.

0 1 2 3 4 5 6

13.1 think of people I enjoy doing things with.

0 1 2 3 4 5 6

14.1 imagine the pain is outside my body.

0 1 2 3 4 5 6

15.1 just go on as if nothing happened.

0 1 2 3 4 5 6

16.1 see it as a challenge and don’t let it bother me.

0 1 2 3 4 5 6

17. Although it hurts, I just keep on going.

0 1 2 3 4 5 6

18.1 feel I can’t stand it anymore.

0 1 2 3 4 5 6

19.1 feel like I can’t go on.

0 1 2 3 4 5 6

20.1 think of things I enjoy doing.

0 1 2 3 4 5 6

21.1 do anything to get my mind off the pain.

0 1 2 3 4 5 6

22.1 do something I enjoy, such as watching TV.

0 1 2 3 4 5 6

or listening to music
23. I pretend it is not a part of me.

0 1 2 3 4 5 6

WHOQOL-BREF

Date:

Name:

Instructions:
This assessment asks how you feel about your quality of life, health, or other areas of
your life. Please answer all the questions. If you are unsure about which response to
give to a question, please choose the one that appears most appropriate. This can often
be your first response.
Please keep in mind your standards, hopes, pleasures and concerns. We ask that you think
about your life in the last week. For example, thinking about the last two weeks, a
question might ask:

Do you get the kind

Not at all

Moderately

much

of support from others
that you need?

Not

1

A great Completely
deal

2

3

4

5

You should circle the number that best fits how much support you got from others over
the last week. So, you would circle the number 4 if you got a great deal of support from
others. You would circle number 1 if you did not get any of the support that you needed
from others in the last week.

100

101
Please read each question, assess your feelings, and circle the number on the scale for
each question that gives the best answer for you:
Very

1(G1) How would you

poor

rate your quality of life?

1

Neither poor

Poor

nor good

2

Very
Good
4

3

Very

Good
5

Neither

2(G4) How satisfied Dissatisfied Dissatisfied Satisfied/

Very
Satisfied

Satisfied

Dissatisfied

are you with your health?
1

2

5

4

3

The following questions ask about how much you have experienced certain things in the
last week:
3(FL4) To what extent

Not at A

A

Very

An

do you feel that physical

all

moderate

much

extreme

little

amount

pain prevents you from
doing what you need to do?

amount

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

4(F1L3) How much do you
need any medical treatment
to function in your daily life?

5(F4.1) How much do you
enjoy life?
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6(F24.2) To what extent do
you feel your life to be

1

2

5

4

3

meaningful?
Not at Slightly A moderate
7(F5.3) How well are you all
able to concentrate?

Very

amount

much

Extremely

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

8(F16.1) How safe do you
feel in your daily life?

9(F22.1) How healthy is
your physical
environment?

The following questions ask about how completely you experience or were able to do
certain things in the last week:

10(F2.1) Do you Not at all

A little Moderately

Mostly Completely

2

3

4

5

2

3

4

5

have enough energy
for everyday life?

1

11(F7.1) Are you able to accept
your bodily appearance?

1
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12(F 18.1) Have you enough
money to meet your needs? 1

2

3

4

5

2

3

4

5

2

3

4

5

13(F20.1) How available to you
is the information that you 1
need in your day-to-day life?

14(F21.1) To what extent do
you have the opportunity 1
for leisure activities?

Very
poor

Neither poor

Very

Poor

nor well

Well

2

3

4

well

15(F9.1) How well
are you able to

1

5

get around?
The following questions ask you to say how good or satisfied you have felt about
various aspects of your life over the last week:
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Very

Neither

Very

Satisfied Satisfied

Dissatisfied Dissatisfied Satisfied/
Dissatisfied

16(F3.3) How satisfied
are you with your sleep?

1

2

3

4

5

2

3

4

5

2

3

4

5

2

3

4

5

2

3

4

5

2

3

4

5

17(F10.3) How satisfied are you
with your ability to

1

perform your daily living activities?

18(F12.4) How satisfied are
are you with your capacity
for work?

1

19(F6.3) How satisfied are you
with yourself?

1

20(F13.3) How satisfied are you
with your personal

1

relationships?
21 (FI5.3) How satisfied are you
with your sex life?

1

22(F14.4) How satisfied are you
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with the support you get

1

2

3

4

5

2

3

4

5

2

3

4

5

2

3

4

5

your friends?

23(F17.3) How satisfied are you
with the conditions of your 1
living place?

24(F19.3) How satisfied are you
with your access to health 1
services?

25(F23.3) How satisfied are you
with your transportation? 1

The following question refers to how often you have felt or experienced certain things in
the last week:

26(F8.1) How often do you Never

Seldom

have negative feelings such
as blue mood, despair,
anxiety, depression?

1

2

Quite

Very

Often

Often

3

Always

4

5

Loma Linda University
Informed Consent

A Psychoeducational Group
Intervention for Fibromyalgia Patients
Research Conducted through Loma Linda University by the Department of Psychology.
Purpose and Procedures
You are being invited to participate in this study so that we may find out how to provide
more effective health care for subjects with a diagnosis of Fibromyalgia Syndrome
(FMS). In particular, we are exploring the effectiveness of an educational group on
improving functioning and decreasing the symptoms of FMS in participants.

This study will consist of group meetings that feature presentations by local experts on
the subject of FMS, with two doctoral psychology students co-facilitating. The experts
will present information and invite any questions you may have. Then, participants will
be asked to fill out a personal workbook on how they can use the information to help
them deal with their FMS symptoms. There will be a different expert presenting each
week. In particular, here are the topics of each meeting, with the expert’s professional
role in parentheses:
1. General information about FMS and known treatments (Rheumatologist).
2. The benefits of exercise and the development of a personalized exercise plan
(Physical Therapist).
3. Enhance self-awareness of thoughts, feelings, and emotions around FMS
(Psychologist).
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4. Learn and practice relaxation techniques (Clinical Social Worker).
5. Develop skills to help economize energy expenditure (Occupational Therapist).

6. Discuss the role of mental health issues that may impact your experience of FMS
(Psychiatrist).
7. Discuss pertinent issues and techniques designed to enhance sleep hygiene

(Psychiatrist).
8. Examine how pain affects relationships (Marriage and Family Therapist).
9. Explore the relationship between trauma and pain (Psychologist/Marriage and
Family Therapist).
10. Debrief and development a treatment maintenance plan.

In order to qualify for the study you will need to be willing to wait for treatment and
complete questionnaires over the internet. There are two phases to the study—one
involves being a part of a treatment group for 10 weeks, and one involves being in a
waitlist group for 10 weeks. You will be randomly assigned to one of the two group.
However, you will definitely receive treatment—either during the first 10 weeks or the
last 10 weeks. We also need you to commit to attending all 10 group meetings and filling
out all weekly surveys so that you can experience the full benefits of group membership.
When filling out surveys online, you will need to be mindful to that surveys are only
filled out by you personally. Also, surveys must be completed every Wednesday between
4:00 - 5:00 p.m. Your participation would involve coming to all weekly meetings,
Wednesdays from 5 - 6:30 p.m. Before leaving for each meeting, you would need to take
about 10 minutes at home on the internet to fill out a short questionnaire that asks
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questions about your current FMS symptoms. At four different times (around the
beginning, middle, and end of treatment), you would also be asked to fill out a longer
version of the online questionnaire. In it you would be asked questions about pain
severity, functional independence, the ways you interpret and cope with problems,
emotional reactions, and quality of life. If you are randomly chosen to wait for treatment,
you would still need to fill out weekly online surveys every Wednesday between 4:006:00 p.m. Feel free to contact the principle investigator of the study, Kendal Boyd, Ph.D.
at (909) 558-8574 or kboyd@llu.edu if you have questions or would like further
explanation.
Risks
The committee at Loma Linda University that reviews human studies (the Institutional
Review Board) has determined that participating in this study exposes you to minimal
risk of any physical or emotional harm.
Benefits
It is hypothesized that this study will benefit you directly; however, this treatment
package is experimental and has not yet been shown to be effective in treating FMS
symptoms or in increasing functioning. This study has the potential to provide long-term
benefits in health care service delivery for individuals diagnosed with FMS. The benefits
of this study not only include helping individuals currently seeking treatment for this
illness, they also include assisting future generations who will be treated by a better
informed team of health care providers.
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Participant’s Rights
Participation in this study is voluntary. If you choose not to continue attending the groups
or fill out the questionnaires it will not affect your health care in any way. After the
conclusion of the study, you may contact the principal investigator to learn the results.
Anonymity/C onfidentiality
Your participation is voluntary and confidential. All meetings will be videotaped for
supervision/training of the students involved and to assure quality. Videotapes will be
reviewed by facilitators and principle investigator at the end of the 10-week treatment
group. Should any concerns of treatment quality arise during 10-week period, videotapes
will be reviewed by facilitators and principle investigator in order to address treatment
issues. These tapes will be stored in a secure, locked office. No staff, faculty, or
personnel outside the treatment team will have access to the videotape or to your
questionnaire responses unless you provide written consent. Tapes will be destroyed after
two years unless you give written permission to have them kept on file for a longer period
of time. The issues explored in the group will be personal to you, but without studies like
these we would not be able to design effective interventions for people suffering from
these difficult conditions.
Additional Costs/Reimbursement
You will be paid the sum of $50 dollars for participating in this study. In order to eligible
for the full amount, you will need to complete all 20 weeks in both the treatment and the
wait/list groups. Should you need to withdraw from the study earlier, you will be given a
prorated amount based on your attendance. For example, if you participate for only the
first 10 weeks, you will receive $25 dollars.
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Impartial Third Party Contact
If you wish to contact an impartial third party not associated with the study regarding any
questions or complaints that you may have about the study, you may contact the Office of
Patient Relations, Loma Linda University Medical Center, Loma Linda, CA 92354,
telephone number (909) 558-4647 for information and assistance.
Informed Consent Statement
Please read and understand the following statement: “I have read the contents of the
consent form and have had a chance to get further explanation from the
investigator. My questions concerning this study have been answered to my
satisfaction. I have received a copy of the California Experimental Subject’s Bill of
Rights and have had these rights explained to me. I hereby give my voluntary
consent to participate in this study. Agreeing to this does not waive my rights nor
does it release the investigators, the institution, or its sponsors from their
responsibilities. I may call Kendal Boyd, Ph.D. at (909) 558-8574, or the Department
of Psychology at (909) 558-8577, should I have additional questions or concerns. I
have been given a copy of this consent form.”

If you agree with this statement, please provide your signature and today’s date.

Signature of Participant

Date

Ill
Signature of Witness

Date

Signature of Investigator

Phone #

UNIVERSITY LIBRARIES
LOMA LINDA, CALIFORNIA

Date

